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Transcutaneous application of vaccines is a promising strategy to enhance the 
effectiveness of vaccination using a reachable route of administration. Additionally, 
replacing the conventional needles with skin mechanical penetration techniques as 
microneedles or skin laser microporation will offer great advantages. This 
transcutaneous delivery techniques are pain-free and will help to avoid the hazards of 
needles. For the delivery of antigens, nanocarriers are so promising to enhance and 
modulate their immune response. The nanocarriers offer merits such as antigen 
protection from degradation, and controlling the release rate of the antigen. 
Additionally, due to the particulate nature of the nanocarriers, they can potentially 
display the antigen in a way that better mimics pathogens. For this aim, ovalbumin as 
a model antigen has been delivered using functionalized theranostic gelatin 
nanoparticles to bone marrow-derived dendritic cells (BMDCs). The nanoparticles 
were rendered fluorescent by using a novel imaging agent (gold and silver alloy 
nanoclusters) that emits near-infra red light. This was beneficial to study the 
nanoparticles uptake by BMDCs and also to image the nanoparticles within the skin 
tissue. Finally, the developed theranostic nanocarriers induced the maturation of the 
BMDCs and enhanced the proliferation of both helper T cells (CD4+) and cytotoxic T 
cells (CD8+). This indicates the potential efficacy of the delivery system for vaccination 



























Die transkutane Applikation von Impfstoffen ist eine vielversprechende Strategie, um 
die Wirksamkeit der Impfung auf einem gut erreichbaren Verabreichungsweg zu 
erhöhen. Zusätzlich bietet der Ersatz von konventionellen Nadeln durch mechanische 
Penetrationstechniken der Haut, wie Mikronadeln oder Hautlaser-Mikroporation, große 
Vorteile. Diese transkutane Verabreichungstechnik ist schmerzfrei und wird dazu 
beitragen, die Patientencompliance zu erhöhen. Für die Darreichung von Antigenen 
stellen Nanocarrier eine vielversprechende Arzneiform dar, da sie die Immunantwort 
verstärken und modulieren können. Die Nanocarrier bieten Vorzüge wie den Schutz 
des Antigens vor Abbau und die Kontrolle der Freisetzungsrate des Antigens. Darüber 
hinaus können die Nanocarrier aufgrund ihrer partikulären Beschaffenheit das Antigen 
potenziell so präsenteieren, wie es Krankheitserreger tun. Zu diesem Zweck wurde 
Ovalbumin als Modellantigen unter Verwendung funktionalisierter theranosticher 
Gelatine-Nanopartikel in dendritische Zellen aus Mäuseknochenmark eingebracht. Die 
Nanopartikel können mit neuartigen Fluoreszenzsonden (Nanocluster aus Gold- mit 
Silber) markiert werden, die rotes Licht im nahen Infrarotbereich emittieren. Dies war 
vorteilhaft, um die Aufnahme der Nanopartikel durch die dendritischen Zellen zu 
untersuchen und auch um die Nanopartikel im Hautgewebe abzubilden. Schließlich 
induzierten die entwickelten theranostischen Nanocarrier die Reifung der dendritische 
Knochenmarkszellen und verstärkten die Proliferation von T- Helferzellen als auch der 
zytotoxischen T-Zellen. Dies deutet auf die potenzielle Wirksamkeit der Formulierung 











































1.  Introduction 
Transcutaneous delivery of drugs and macromolecules is an attractive route of 
administration, due to the accessibility of skin, being the largest organ (weighing 5-6 
kg and covering an average area of 1.7 m2) (1) and the outermost layer of the body. 
Skin functions as a barrier to protect the body from exterior radiation or microorganisms 
and from internal water loss that can lead to dehydration. Besides being a mechanical 
barrier, skin has immunological function by acting as the first line defense when 
antigens or microorganisms invade the body through skin. It is rich in antigen 
presenting cells (APCs) in both the epidermis and dermis, which have a role in both 
innate and adaptive immunity. Making use of such function renders skin an attractive 
site for immunization (2). 
 
1.2. Skin anatomy 
Skin composes of three main layers (Figure 1): epidermis (the outer most layer), 
dermis, and subcutaneous fat tissue. The epidermis is the outer most layer of skin of 
50 to 150 μm thickness. Stratum corneum represents the surface upper layer of the 
epidermis with 15–20 μm thickness. It is responsible for the barrier function of skin with 
a rigid bricks and mortar structure. They consist of keratinized epithelial cells 
(coenocytes, bricks) connected by desmosomes and embedded in intercellular lipids, 
mainly ceramides, cholesterol and saturated long chain fatty acids (3), of organized 
lamellar structure (mortar). Laying beneath is the viable epidermis, consisting of mainly 
keratinocytes and other cell classes as melanocytes, Merkel cells and Langerhans 
cells. Below the epidermis, locates the dermis that consist of fibroblasts, mast cells, 
and dermal dendritic cells. This skin layer contains blood vessels, lymph vessels and 
nerves. It is responsible then for exchanging fluids with blood and skin and skin 
sensation as well. Deeper in skin, lays the subcutaneous tissue that consists of 
adipocytes to act as a thermal barrier. Skin also has appendages such as sweat 
glands, pilosebaceous units, and hair follicles that originate from the dermis or the 
subcutaneous tissue toward skin surface (2). 
 
1.3. Skin barrier  








diffusion of molecules of molecular weight higher than 500 kDa (5). Additionally, the 
material’s hydrophobicity matters as partition coefficients (logP) between 1 and 3 
represent the optimal for skin absorption (6). Pathways for skin absorption are through 
skin SC; intercellular or intracellular pathway or through skin appendages 
(transfollicular pathway) (4). The intercellular pathway is the main pathway, where 
molecules diffuse through the spaces between crystalline lipid lamellae and their 
adjacent cells’ outer membrane (7). On the other hand, the intercellular pathway is 
unlikely of importance for materials diffusion through the rigid corneocytes, which are 
dead cells filled with keratin and surrounded by an impermeable cornified envelop (2, 
6). Transfollicular pathway has gained interest recently, for topical or transdermal 
delivery of nanoparticles. The hair movement is claimed to pump the nanoparticles into 
the hair follicle (8), which can act as a depot for nanoparticles to release the drug for 
the treatment of skin diseases. However, the efficiency of the follicular delivery is highly 
affected by the particle size. On the other hand, the follicular orifices represent only 















Figure 1.    Skin structure showing different skin layers and their structures, a) stratum corneum 
(uppermost layer), b) epidermis which composes mainly of keratinocytes, c) hair follicle, d) 














1.4. Skin immunology 
Skin plays an important role in both innate and adaptive immunity. Innate immunity, 
known as natural immunity, is naturally present at birth. It is the first line defence in 
form of an immediate non-specific immune response, when antigen is introduced to 
the body as a ‘danger signal’, using defensive tools such as fever, the complement 
system, phagocytic and natural killer cells, naturally occurring antibodies and 
antimicrobial peptides. Adaptive or acquired immunity is a learned, specific immune 
response to an antigen due prior-sensitization, with long term immunological memory 
(9). When skin barrier is disrupted and keratinocytes, which represents 90–95% of the 
total epidermis cells (10), find a danger signal, they start an innate immune response 
by releasing cytokines, chemokines and antimicrobial peptides (11). They also release 
cytokines, granulocyte-macrophage colony-stimulating factor (GM-CSF) and tumor 
necrosis factor-α (TNF-α), to induce the maturation and migration of dendritic cells (10).  
 
Dendritic cells are sentinels of immunity and tolerance. They are antigen presenting 
cells (APC). They are responsible and capable of taking antigens from the periphery 
to lymphoid tissues (12). They also transfer the signals from innate to adaptive immune 
system by regulating T-cell differentiation. There are two types of dendritic cells present 
in skin: a) Langerhans cells which are located in the epidermis. They are much fewer 
than keratinocytes (only 2%), but they are large in size with many appendages that 
connect to form a network and b) dermal dendritic cells (interstitial DCs), which locate 
in dermis (13). Immature dendritic cells always scan the surroundings for foreign 
bodies (14) (Figure 2). They recognize pathogens and antigens through pattern 
recognition receptors (PRRs) which are classified into 2 groups (15): a) endocytic 
PRRs: they can phagocytose microorganisms and bind to carbohydrates. They include 
mannose receptor (MR), glucan receptor and scavenger receptor, b) signaling PRRs: 
they include membrane bound toll-like receptors (TLR) (including receptor kinases and 
C-type lectin receptors) and cytoplasmic NOD-like receptors. The recognized antigen 
cause maturation of dendritic cells and their migration to lymph nodes. The DCs 
process the phago- or endocytosed antigens into small fragments during their 
maturation to display them on their surfaces by major histocompatibility (MHC) 








receptors that help for activating T-cells as CD80, CD86 and CD40. They present the 
antigens to helper T-cells (CD4+) or cytotoxic T-cells (CD8+) to activate them to start 





















Figure 2. Uptake and processing of nanoparticles by dendritic cells in skin dermis and dendritic 
cells migration to lymph nodes to present the processed antigen to T-lymphocytes.  
 
 
1.5. Transcutaneous vaccination 
Vaccination is developing an immunological memory of the adaptive immune system 
against a specific disease. There are different types of vaccines (17): a) live-
attenuated: contains attenuated live viruses that cannot cause disease, b) inactivated 
or killed: contains inactivated pathogens, c) toxoid: contains weakened toxins taken 
from pathogens, d) subunit: contains part of pathogen’s antigen, e) conjugated: 








synthetic peptide and g) DNA: contains genetic material from the pathogen. 
Conventional vaccines are administrated usually by injection. However, this method is 
painful and needles and syringes can cause many problems including the possibility 
for injury or disease transmittance. They also need trained personnel and special 
storage and transport. Consequently, the development of needle-free painless 
methods is a prerequisite. The transcutaneous route is gaining high interest due to the 
richness of skin in immune cells and easy accessibility to skin. However, methods for 




Microneedle technologies are gaining high interest for transcutaneous delivery of 
medical cargos as pain-free and easy-to use products that may waive the use of 
needles in the future. They are designed as patches with arrays of micron-sized 
projections (50–900 μm long) ‘microneedles’ which can be inserted into skin to 
overcome the SC barrier and reach the viable tissue. Microneedles are required to be 
with minimum length and sufficient mechanical strength to be able to overcome the 
elastic deformation of skin and pierce it (19). There are different types of microneedles: 
solid, hollow, dissolvable and swellable. 
a) Solid microneedles: Among the materials that were first investigated for 
manufacturing solid microneedles were silicon, titanium, and stainless steel. They 
are either in form of patch, punch or roller such as the dermaroller, which is 
commonly used for cosmetics purposes (19). They rely on ‘poke and patch’ 
approach, where the microneedles poke the skin to create micro-channels followed 
by application of drug loaded-patch to allow for drug diffusion into skin (20). Another 
approach is soaking the microneedles in drug solution prior to insertion into skin 
(19). Modification of the solid microneedles manufacturing has been introduced by 
coating their surface with a layer containing the drug to be known as ‘coated 
microneedles’ (21). Regarding the safety, microneedles made of silicone are not 
preferable due to the probability of breaking of the microneedles’ tips in skin that 








formed in skin to close shortly after removal of the microneedles to avoid the 
permeation of undesirable materials or pathogens (23). 
b) Hollow microneedles: They are fabricated with hollow channels inside to allow drug 
transfer (up to 200 μl) into skin from a reservoir. In other words, they resemble in 
design the hypodermic needles. The fabrication of the hollow interior of the 
microneedles, makes the process more complex. Additionally, the absence of the 
internal support compared to solid microneedles, can result in their fracture if not 
inserted properly, especially for the microneedles with high aspect ratio (19). They 
are used for the delivery of biomacromolecules including proteins and 
oligonucleotides (24). They can deliver drugs with large doses, but the flow rate 
needs to be adjusted to keep the flow to avoid accumulation of drugs in the space 
inside the microneedles. Also the flow rate can be accelerated if a rapid bolus 
injection is necessary (25). On the other hand, the microneedles with such hollow 
designs were applied for interstitial fluid sampling for monitoring or diagnosis (26). 
c) Dissolving microneedles: This type of microneedles is gaining growing interest (27-
34). They are prepared out of biodegradable polymers matrices which encapsulate 
the drug to fulfill the strategy of “poke and release”. After the insertion in skin, the 
microneedles stay in skin to dissolve to release the drug. So, it is a single step 
application, which enhance patient compliance (24). Microneedles patches can be 
applied by patients themselves, either manual, by thumb pressing, or by using an 
applicator. Another important advantage is that this type of microneedles don’t 
leave environmental waste behind, which is a significant problem when it comes to 
the disposal of hypodermic needles (35). Micromolding is the main fabrication 
method adopted in different labs. The microneedles are formed by pouring the 
polymer/drug mixture into a mold which is usually made out of polydimethylsiloxane 
(PDMS). The dying of the microneedles is usually done under ambient conditions, 
which is important for delivery of thermolabile biomacromolecules as protein and 
peptides (24). 
d) Hydrogel-forming (swellable) microneedles: They compose out of super-swelling 
polymers that absorb large amounts of interstitial fluid when inserted into skin, so 
they expand and become porous allowing for drug release (36). Additionally, they 








1.5.2. Laser microporation 
Skin microporation using laser or fractional laser ablation is a recently-introduced 
approach for transcutaneous delivery of antigens. A pulsed infra-red laser is used for 
controlled ablation of skin. The water content of tissue highly absorbs the energy of the 
near infra-red light and evaporates rapidly. This generates pressure that disrupts the 
tissue and results in expelling of the cellular content form the site of laser application 
(38). Increasing the energy of applied laser light (fluence), pulse duration and 
frequency would result in higher ablation efficiency. However, long pulses and high 
repetition rate would result in heat generation and thermal injury. This can be avoided 
by using high energy pulses with short duration (lower than the water relaxation time), 
so transfer of heat to surrounding tissue can be neglected (39).  
 
Different lasers have been utilized for skin microporation such as Nd:YAG lasers [48] 
and CO2 lasers. Nd:YAG laser has a wavelength of 2940 nm, which coincide with the 
absorption peak of water. It can induce ‘cold ablation’ i.e. with negligible heat transfer 
to the surroundings when compared to CO2 lasers (40). Novel devices are in the 
market now, in which the laser beam splits into an array of smaller microbeams that 
disrupt the upper layer of skin and induce pore-formation only at the site of exposure 
to the laser light leaving the tissue in between intact. This results in an array of pores 
in skin where the density of pores per unit area can be controlled. This is an advantage 
for decreasing the ablated area of skin and allowing for faster healing (40). Fractional 
laser ablation is an attractive method for transcutaneous vaccination. The applied laser 
can enhance the immune response against the applied antigen. The laser creates 
pores in upper layer of skin (epidermis or epidermis-dermis junction). Additionally, it 
creates a pro-inflammatory environment, where immune cells in skin including dendritic 
cells get triggered, uptake the applied antigen and become activated to transfer the 
antigen to secondary lymphoid organs, to activate T-cells and induce immune 
response. In contrast, intradermal immunization delivers antigens deep in skin, where 












Electroporation method involves the application of electric pulses of short duration and 
high voltage (75–100 V) to skin surface. The applied current creates transient pores in 
the lipid bilayer membrane of cells, so can enhance the permeability of molecules (42, 
43). The technology has been reported for successful delivery of antigens (44) and 
DNA vaccines (45). Additionally, the electric pulses themselves have an adjuvant effect 
on the immune system by recruiting and triggering the immune cells in skin (45, 46). 
Although the technique was developed for use in medical institutions, as a power 
supply equipment is required, new series of hand-held cordless electroporation device 
became available (47). 
 
1.5.4. Sonophoresis 
In sonophoresis, low-frequency ultrasound (20 to 100 kHz) (48) is applied to skin 
surface. The ultrasound cause cavitation, which results in formation of gas bubbles in 
the tissue. This loosens the integrity of the SC and thus enhance the permeability. Two 
types of cavitation can be generated; either transient cavitation, which is a rapid 
enlargement and collapse of the bubbles, or stable cavitation, which is slow oscillatory 
motion of the bubbles (49). Additional physical adjuvant effect of the ultrasound on 












Figure 4. Different methods for transcutaneous delivery of macromolecules and nanoparticles, 
A) microneedles, B) skin microporation using pulsed infrared laser, C) electroporation, D) 
sonophoresis and E) transdermal patch and tape-stripping. 








1.5.5. Jet injectors 
Jet injectors are needle-free devices that use high-velocity jets (100 to 200 m/s) to 
deliver materials into skin or even to the muscles. They consist of a power source 
which is compressed gas or a spring, a piston, a compartment filled with the drug 
solution and a small nozzle that is 150-300 μm in size (51). By actuation, the device 
releases the drug solution through an orifice with high velocity to hit the skin creating 
a hole to deliver the drug through skin. The whole process of skin penetration takes 
just microseconds. The devices can be in form of multi- or single-use jet injectors 
depending on the number of injections the device contains (47). 
 
1.5.6. Transdermal patches 
Conventional transdermal patches have been well-known for their occlusive effect to 
transfer drugs into skin. SC hydration decreases its barrier integrity and increases the 
permeability of foreign materials into skin (52). Transdermal patches have been used 
for delivery of molecules such as nicotine, estrogen and lidocaine, which are all known 
for their hydrophobicity (53). Additionally, chemical enhancers can be used in the 
formulation of the patches, which can increase skin permeability to small molecules, 
however with limited improvement when it comes to biomacromolecules (52). So, 
combination of patches with other physical penetration methods is a prerequisite for 
transcutaneous delivery of antigens such as ultrasound or electric pulses (53). Tape-
stripping prior to patch application showed to be effective for antigen delivery and 
triggering the immune system as shown by Etchart et al (54). 
 
1.6. Vaccine nanocarriers 
Using nanoparticles for vaccine delivery offers different advantages over the 
administration of soluble antigens. The particles have the ability to induce strong 
humoral and cellular immune response to antigens due to their particulate nature. 
Additionally, they are safer if compared to live attenuated viral vaccines for example. 
Modulation of the nanoparticles physicochemical properties, size, shape and the way 
of antigen encapsulation alongside with the exclusive property to control the rate on 








Different types of nanoparticles have been tested for antigen delivery as will be 
discussed. 
 
1.6.1. Types of antigen nanocarriers 
1.6.1.1. Liposomes 
Liposomes are spherical vesicles formed of a lipid bilayer that self-assembles around 
an inner aqueous core. They are composed of biodegradable non-toxic phospholipids 
and cholesterol. They have either unilamellar or multilamellar structure with several 
concentric lipid shells around the aqueous core, where the antigens can be loaded 
within (55). The liposomes deliver antigens to cells by fusion with the cellular 
membrane (56). They resemble enveloped viruses that are surrounded by parts of the 
cellular membrane of the infected cells. They can perform as adjuvants that stimulate 
the innate immunity (57). Additionally, liposomes may contain viral envelope 
glycoproteins to form virosomes (58). 
 
1.6.1.2. Polymeric nanoparticles 
Polymeric nanoparticles have been widely applied for antigen delivery due to different 
reasons including the biodegradability, biocompatibility, ease of preparation and 
possibility to manipulate their surface properties. The applied polymers are either 
synthetic (e.g. poly (lactic-co-glycolic acid), PLGA) or natural such as polysaccharides 
(e.g. chitosan and alginate) and polypeptides/proteins (e.g. gelatin). PLGA 
nanoparticles have been designed for the delivery of different antigens including 
hepatitis B virus antigen (59), tetanus toxoid (60) and ovalbumin (61) and 
oligonucleotide delivery as well (60). PLGA is a well-tolerated biodegradable polymer. 
It degrades slowly by bulk erosion mechanism which is helpful for controlling the 
release rate of antigen. The degradation rate is faster with higher degree of the polymer 
hydrophilicity, which is controlled by the ratio of the glycolic and lactic acid (62).  
 
On the other hand, among the natural polymers that have been gained interest for 
antigen delivery is gelatin. Gelatin is biocompatible and of low immunogenicity. It is an 
attractive polymer for antigen delivery due to its hydrophilic nature (63). It is a 








results in two different types of gelatin: type A and B, respectively. They have different 
isoelectric points (IEP): 7-9 for type A and 4-5 for type B. The latter show better 
potential for drug and DNA delivery (64). Due to its protein nature, gelatin possesses 
many functional groups which give the opportunity for nanoparticles surface 
modification by ligands for example for targeted antigen delivery (63). The preparation 
and loading of the antigens can be done under non-harsh conditions which is 
necessary for preserving the conformation and the activity of antigens. They can be 
loaded by adding the antigens before the preparation of the nanoparticles or even after 
the preparation by soaking the nanoparticles in the antigen solution or by chemical 
interaction of the antigen to the nanoparticles surface (64). This different techniques 
can offer different functions such as controlling the release rate, antigens protection 
and antigen display mimicking the natural presentation by pathogens. Gelatin 
nanoparticles have been investigated for the delivery of antigens such as tetanus 
toxoid (65) and ovalbumin (66) and DNA as hepatitis C virus recombinant NS2 gene 
(67).  
 
The prepared nanoparticles are required to be cross-linked to keep the nanoparticles 
structure and prevent their solubility in water. Among the most commonly used cross-
linking agents is glutaraldehyde which is a non-zero length cross-linker that links both 
the amine and carboxylic groups of the amino acids (68). However, glutaraldehyde is 
reported for its cytotoxicity (69). On the other hand, carbodiimide cross-linkers seem 
to be promising alternatives to avoid the cytotoxicity of glutaraldehyde as they are zero-
length cross linkers, such as 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDC) 
(70) and N,N′-Diisopropylcarbodiimide (DIC) (71). Different simple techniques have 
been adapted for gelatin nanoparticles’ preparation such as: 
a) Nanoprecipitation: In this technique, aqueous solution of gelatin and the drug is 
added to an antisolvent (which is miscible with water such as acetone or ethanol) 
containing a stabilizer (such as poloxamer). Solvent displacement results in 
nanoparticles formation that will be further cross-linked (72). 
b) Two-step desolvation: The technique depends on the introduction of gelatin 
solution to an antisolvent for gelatin precipitation. This is done over two steps: the 








get rid of the low molecular weight gelatin chains that can cause further irreversible 
aggregation of the nanoparticles. The high molecular gelatin is then dissolved and 
the drug is added to be further precipitated as nanoparticles. The procedure results 
in formation of nanoparticles with homogenous particle size (70). 
c) Simple coacervation: This can be achieved by adding salt or alcohol to charged 
macromolecules that results into liquid-liquid phase separation. Two immiscible 
phases, which are in equilibrium, are formed then: a dense coacervate phase and 
a diluted one (73). 
d) Microemulsion: W/O microemulsion is formed when gelatin aqueous solution is 
added to an organic solvent (immiscible with water) containing surfactant, using 
high homogenization speed, followed by nanoparticles cross-linking and solvent 
evaporation (74). 
 
1.6.1.3. Inorganic nanoparticles 
Some biocompatible inorganic nanoparticles have been investigated for antigen 
delivery. These include gold nanoparticles, mesoporous silica and carbon nanotubes. 
They can be synthesized with a precisely controlled size and shape and their surface 
can be easily modified (55). For example, antigens have been coupled to the surface 
of gold nanoparticles to induce an immune response (75). Gold nanoparticles with 
different shapes can induce different immune responses. In an immunological study 
done by Niikura et al., gold nanospheres and nanocubes induced tumor necrosis 
factor-α (TNF-α), IL-6, IL-12 and granulocyte macrophage colony-stimulating factor 
(GM-CSF), while gold nanorods induced interleukin-1β and IL-18 through an 
inflammasome-dependent mechanism (76). 
 
1.6.2. Advances in nanoparticles formulations for antigen delivery 
1.6.2.1. Antigen encapsulation vs antigen display 
Antigen delivery using nanoparticles has proven to be more effective than the 
administration of soluble antigen. Nanoparticles can act as a delivery system for 
antigens either by delivery of the antigen and being co-digested inside the cell or being 
a transient delivery system by protecting the antigen to release it at the target location 








to provide certain advantages to the delivery system (Figure 4A). Encapsulation of the 
antigen within the nanoparticles’ matrix allows for antigen protection. On the other 
hand, association of the antigen on the surface of the nanoparticles allows for multiple 
antigen display which mimic the natural display of antigens on the pathogen and can 
enhance the immune response. Surface loading can be achieved by: a) chemical 
conjugation to functional groups on the surface of the nanoparticles, b) electrostatic 
interaction between oppositely charged antigens and the nanoparticles and c) physical 
adsorption as in case of inorganic nanoparticles where antigens attach to the surface 
of gold nanoparticles, by weak interaction forces forming a protein corona, preventing 
the aggregation of the nanoparticles (57). 
 
1.6.2.2. Adjuvants delivery 
In addition to using the nanoparticles for the delivery of antigens, they have been used 
for adjuvants delivery for enhanced immune response. Different strategies have been 
followed for delivering adjuvants by nanoparticles. Co-delivery of both the antigen and 
the adjuvant has been studied by association to the surface of the nanoparticles, so 
both of them are exposed to the immune cells (Figure 4A). Liu et al have functionalized 
PLGA nanoparticles with both hepatitis B surface antigen and TLR9 agonist 
unmethylated cytosine‐guanine (CpG) adjuvant (78). Another method for adjuvant co-
delivery with antigens is loading them separately using the same or different types of 
nanocarriers. Hanson et al have co-delivered low immunogenic HIV antigen liposomal 
formulation, with cdGMP adjuvant loaded in PEGylated lipid nanoparticles (79) (Figure 
4A). 
 
1.6.2.3. Delivery to lymph nodes 
Particle size of the nanoparticles is a determinant for their cellular interaction and their 
distribution after administration. Nanoparticles strongly help to target the antigens to 
lymph nodes in comparison to soluble antigens. Particles with size 10-100 nm are 
drained directly to lymph nodes where they can be taken up by resident immune cells 
as macrophage and dendritic cells (80, 81) (Figure 4B). On the other hand, particles 
larger than 100 nm stay at the administration site to be taken up and processed by 








to present the processed antigen fragment to T cells (81, 82) (Figure 4B). 
 
1.6.2.4. Interaction with dendritic cells 
Different properties of nanoparticles modify their interaction with cells including size, 
shape and charge. Nanoparticles with comparable size to pathogens can be 
recognized by APCs easily. Particles of size 20-200 nm which mimic the viruses’ size 
are preferably taken up by dendritic cells, while larger particles of 0.5-5 µm are taken 
up by macrophages (83). Particles’ shape is important for detecting how they interact 
with cells. For example, spherical particles showed higher phagocytosis by 
macrophage compared to the negligible uptake of worm-like particles with aspect ratio 
> 20 (84). Considering the surface charge, positively charged particles have higher 
ability to be taken up by APC due to their interaction with the negatively charged cell 
membrane (85) (Figure 4C). 
 
On the other hand, targeting dendritic cells is a promising strategy for activating the 
dendritic cells and increasing the efficiency of vaccination (Figure 4C). Dendritic cells 
can recognize antigens through different types of receptors as C-type lectin receptors 
(CLRs) and Toll-like receptors (TLRs) (86). Functionalization of nanoparticles by 
suitable ligands to target a specific receptor can enhance antigen capture by dendritic 
cells through receptor-mediated endocytosis. For example, DCs have a specific 
intercellular adhesion molecule-3-grabbing non-integrin (DC-SIGN) which is a type of 
DCs lectin that recognizes mannose clusters exposed by many pathogens. This 
approach has been utilized for targeting functionalized gold nanoparticles to dendritic 
cells through carbohydrate-lectin interactions, so the particles can be internalized to 
the cytosol (87).   
 
After DCs recognize and capture the antigen, they process it into small fragments and 
transfer them to MHC molecules to be exposed on the cellular surface and presented 
to T cells (Figure 5). Exogenous antigens are loaded into MHC II molecules to be 
presented to CD4+ cells that become activated and differentiate into T helper cells 
(Th1, Th2, Th1) and Tregs that release cytokines to activate other immune cells such 






































Figure 4. Advances in nanoparticles formulations for antigen delivery and effective 
vaccination, a) different ways for antigen delivery by encapsulation or surface display of the 

















either by size targeting ( > 100 nm) to be taken up by resident macrophages or by migratory 
dendritic cells for nanoparticles < 100 nm and c) targeting of  nanoparticles to dendritic cells 





















Figure 5. Antigen processing and presentation by dendritic cells through two different 
pathways: 1) For exogenous antigens: a) endocytosis, b) endosome formation, c) enzymatic 
fragmentation of the antigen and d) presentation by MHC II to CD4+. e) cross-presentation in 
case of endosomal escape of the antigen to the cytosol to be processed as an endogenous 
antigen. 2) For endogenous antigens, f) cytosolic antigens, g) antigen processing by 























cells are loaded into MHC I to be presented to CD8+ cells that differentiate into 
cytotoxic T cells (CTLs) that kill infected or tumor cells (86). Cross presentation is the 
ability of APCs to present exogenous antigens to MHC I to activate CD8+ cells (Figure 
5). This is important for vaccination against viruses and tumors. This can be achieved 
either by antigen uptake to the cytosol or antigen escape from the lysosome to cytosol 
to be degraded by proteasomes. Nanoparticles could show the ability to enhance 
antigen cross presentation as a potential strategy for developing effective cancer or 
anti-virus vaccines. Experiments indicated that different particles showed the ability to 
induce antigen cross presentation in DCs such as γ-PGA NPs (88), PLGA NPs (89), 
polyethyleneimine NPs (90). The antigen cross presentation can be fortified by 
controlling the particle size and surface chemistry of the nanoparticles (91, 92). 
 
1.7. Imaging of nanoparticles in skin 
Imaging and tracking nanoparticles in skin is a prerequisite to assure the effectiveness 
of therapy or to study nanoparticles fate and cytotoxicity. This can be applied to track 
nanoparticles passive penetration or with using a penetration enhancement method as 
microneedles (93). It can also reveal the interaction of nanoparticles with biological 
tissue and cellular uptake. However, imaging in skin is a challenging task. Among the 
techniques commonly used for nanoparticles imaging in skin is confocal laser scanning 
microscopy (CLSM). It is known for its availability and ease of use for detection of 
fluorescent probes. It is a sensitive, selective and versatile method for fluorescence 
measurements. It can provide high resolution imaging with non-invasive optical 
sectioning and three-dimensional reconstructions of samples (94). Additionally, 
minimum or no sample preparation is required which is advantageous to avoid 
perturbation or damage to the tissue (95). However, on the other hand, CLSM is not 
the most superior technique when it comes to penetration depth and contrast when 
compared to multiphoton microscopy for example (96).  
 
Skin is a challenging tissue for fluorescence imaging due to its density that reflects and 
scatters incident light, in addition to skin’s endogenous chromophores that attenuate 
visible light. Skin is autofluorescent over a wide range of wavelengths due to the 








etc (97), which can interfere with the detection of many fluorescent probes. For this 
reason, the process of selecting an ideal fluorophore for imaging in skin is not an easy 
task. It is necessary to select fluorophores with distinct emission spectra from that of 
skin (95). On the other hand, to minimize the interference from skin autofluorescence, 
the imaging setup can be optimized to offset the skin fluorescence before imaging the 
fluorescent probe (98, 99) which is only possible for strong fluorescent signals. This 
renders the simultaneous imaging of skin and exogenous fluorophores challenging. 
One method can be the pre-staining of skin with another fluorophore with minimum 
cross-talk to the fluorophore under test, so both of them can be imaged simultaneously 
(100). However, simpler and time-saving methods are required. In this regard, we 
introduce through this research work a method for simultaneous imaging of skin and 
fluorophores using spectral analysis and linear unmixing. The method depends on 
recording the emission spectrum of the sample and efficiently separate it into the 
individual components using the pre-recorded emission spectra of the components 
(fingerprints) as references based on a mathematical algorithm (101).  
 
1.7.1. Different imaging agents for nanoparticles tracking using CLSM 
1.7.1.1. Dyes 
Dyes represent the most common fluorophores for nanoparticles imaging. They are 
either covalently bound to the nanocarriers or physically loaded and distributed within 
the particles. Usually, the imaging probe is selected to have similar physicochemical 
properties to the drug under investigation. Derivatives of rhodamine and fluorescein 
are well known dyes for imaging of nanoparticles in skin. Rhodamine is a lipohophilic 
dye that can be used for labelling of lipid-based nanoparticles (99). On the other hand, 
fluorescein can be used for conjugation with polymeric delivery systems such as 
dendrimers (102).  
 
1.7.1.2. Quantum dots 
Quantum dots are fluorescent semiconductor inorganic nanocrystals (2-10 nm) that 
show material- and size-dependent emission (103). They usually have high quantum 
yield and are resistant to photobleaching. Generally, they compose of a cadmium 








However, Cd can be released form the core to the medium and cause cytotoxicity. 
Consequently, surface modifications as coating (e.g. with poly ethylene glycol) or 
charge modification are required to control their toxicity (104). Quantum dots were used 
themselves as a fluorescent model for nanoparticles to test their ability to penetrate 
skin (104, 105) or have been loaded in nanocarriers (e.g. ethosomes) as an imaging 
probe (106). 
 
1.7.1.3. Gold nanoclusters    
Gold nanoclusters are ultra-small (< 2nm) particles that compose of several to 
hundreds of gold atoms that are stabilized by ligands of different functional groups 
mainly proteins and peptides (107). Their ultra-small size is comparable to the Fermi 
wavelength of electrons. In this size range, the strong quantum confinement of the free 
electrons results in discrete electronic states and consequently gold nanoclusters show 
molecule-like properties (108). They are different form larger gold nanoparticles, as 
they do not exhibit Plasmon resonance. Instead, they absorb and emit light in the 
visible or near infra-red range (109). They show superior photochemical stability 
compared to organic fluorophores. The tunable emission wavelength of the 
nanoclusters offers wide variability in applications, including bioimaging and 
biosensing (108). These nanoclusters have been widely used for cell and in vivo 
imaging (108). For example, functionalization of gold nanoclusters with molecules such 
as folic acid will dedicate them for cancer cells recognition (110). In addition, they 
showed success in live cell imaging to monitor the real-time cellular changes (111). On 
the other hand, gold nanoclusters have been used for in vivo imaging in animal models 
(mice) when injected intravenously to monitor their body distribution (112, 113). 
Different methods have been studied for gold nanoclusters preparation: 
a) Gold salt reduction: Gold ions Au (III) are partially reduced in the presence of thiols 
into Au (I) thiolate oligomers.  Addition of a strong reducing agent as NaBH4 results 
in the complete reduction of gold ions into Au (0). Aggregation of Au atoms is 
controlled by the excess thiols to form nanoclusters of uniform size (114). 
b) Templated synthesis using macromolecules: Proteins, DNA, dendrimers and other 
macromolecules can be utilized as a template for stabilization of the nanoclusters 








dispersability, biocompatibility, ease of conjugation, large stroke shift and long 
lifetime, which make them a good choice for bioimaging (115). Additionally, 
proteins are biologically active moieties that can fulfill a desired function (114).  
c) Chemical Etching: Gold nanoclusters can be prepared from larger gold 
nanoparticles by ligands acting as etching agent, which etch gold atoms from the 
surface of gold nanoparticles, then stabilize the atoms to form stable gold 
nanoclusters (116). 
 
Different factors control the fluorescence properties of gold nanoclusters including their 
size, structure, oxidation states, interaction with the ligand and environmental 
conditions such as temperature, pH and ionic strength (115).  
a) Size: The fluorescence mechanism of gold nanoclusters is not completely 
understood, but different factors have been studied to understand more about 
their structure-properties relationship. Gold nanoclusters have a general 
structure of metal core-shell that is stabilized by ligands forming staple-like 
motifs on the surface (117). The number of gold atoms in the core controls the 
fluorescence properties of the nanoclusters. It has been reported that changing 
the core size from Au12 to Au6 resulted in increase in the quantum yield from 
0.57 to 3.15% (118).  
b) Oxidation state: The oxidation state of Au is affecting the final fluorescence 
properties of the nanocluster. For thiolated-nanoclusters, the fluorescence 
depends on the electron transfer from S to Au. The oxidation state of the gold 
core is highly affecting the charge transfer efficiency and thus the fluorescence 
(115). 
c) Ligand effect: Ligands play an important role in controlling the properties of 
gold nanoclusters, due to the charge transfer from ligand to the metal core 
(119). For thiolated gold nanoclusters, increasing the electron donation 
efficiency of S or the ligand density on the nanoclusters surface can enhance 
the fluorescence (115).  
 
Gold nanoclusters have been encapsulated in several drugs nanocarriers to function 








our current research, we contribute toward the application of gold nanoclusters by 
loading them in gelatin nanoparticles for imaging in a dense challenging tissue as 
human skin. Furthermore, we tried to elicit the organisation of additional silver atoms 
and the resulting structures. 
 
1.8. Disclosure 
Figures of the introduction were created with the aid of BioRender and Servier medical 
art. 
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2. Research Objectives  
 
Nanoparticles have gained the interest for vaccine delivery due to their ability to provide 
interesting functionalities such as antigen protection against degradation, controlling 
the release rate of the antigen, presenting the antigen to dendritic cells in a way that 
mimics pathogens. In turn, enhancement and modulation of the immune response can 
be achieved. Transcutaneous administration of nanoparticles is an attractive route of 
vaccination due to the richness of skin in immune cells. For this purpose, nanoparticles 
have to be combined with skin penetration methods such as microneedles or skin laser 
microporation. These techniques allow the nanoparticles to bypass the stratum 
corneum, which is the main barrier of skin, to the viable skin (epidermis or dermis) 
where Langerhans cells and dermal dendritic cells locate. For better understanding of 
the nanoparticles interactions with dendritic cells and for nanoparticle tracking in skin, 
development of theranostic nanoparticles is required. However, imaging together with 
or in a dense and autofluorescent tissue such as skin is challenging. Consequently, an 
optimal biocompatible imaging agent that emits near infrared light, which is the optical 
window of tissue, is required. 
 
Accordingly, the current thesis aims to fulfill the following objectives: 
Chapter 3: Development of gold nanoclusters as a novel imaging agent that emits light 
in the near infrared region. This can be achieved by: 
- Synthesis of gold nanoclusters using gelatin and further formulation of gelatin 
nanoparticles. 
- Optimization and enhancement of the fluorescence properties of gold 
nanoclusters and deeper insights into of their structure-properties relationship. 
- Imaging of the fluorescent gold nanoclusters-modified gelatin nanoparticles in 
human skin. 
-  
Chapter 4: Development and customization of dissolving microneedles loaded with 
the nanoparticles for transcutaneous delivery. This can be achieved by: 
- Using 3D printing as an accessible and cost-effective method for developing 
master molds of variable designs to further use it for microneedles preparation. 







- Preparation of microneedles with special ‘tanto blade’ design and modification 
of the microneedles patches to fasten the microneedles separation from the 
patch into skin to decrease the application time. 
- Loading of the fluorescent gold nanoclusters-modified gelatin nanoparticles into 
the microneedles and imaging them in vitro and ex vivo in human skin. 
 
Chapter 5: Delivery of ovalbumin to dendritic cells using the developed theranostic 
gelatin nanoparticles and modulation of the immune response. This can be achieved 
by: 
- Introducing two designs of the nanoparticles by either loading ovalbumin to the 
surface of the nanoparticles or encapsulating it within the matrix of the 
nanoparticles. 
- Surface functionalization of the nanoparticles to enhance the interaction and 
uptake by dendritic cells 
- Studying the effect of the nanoparticles formulations on the activation of 
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3. NIR-Emitting Gold Nanoclusters-Modified Gelatin Nanoparticles as 
a Bioimaging Agent in Tissue 
3.1. Abstract  
Gold nanoclusters (AuNCs) synthesis using gelatin which is a well-distinguished 
polymer for nanoparticle-mediated drug delivery, will open the door for developing 
efficient theranostics based on pharmaceutically accepted materials. Gelatin-stabilized 
AuNCs have been synthesized and for tuning the emission spectra, they were further 
modified using glutathione. Moreover, the addition of silver ions to the preparation 
enhanced the fluorescence to reach a high quantum yield of 26.7%. We have 
developed a hypothetic model describing the nanoclusters’ properties-structure 
relationship based on X-ray photoelectron spectroscopy data and synthesis sequence. 
Additionally, these modifications have improved the fluorescence stability toward pH 
changes and enzymatic degradation. The effect of nanoclusters formation on the 
integrity of gelatin structure has been explored using FT-IR and MALDI-TOF MS, being 
important to further formulate gelatin nanoparticles (GNPs). The prepared 218 nm-
sized NPs showed no cytotoxicity up to 600 µg/mL against keratinocytes and have 
been imaged in skin, which is a challenging autofluorescent tissue using confocal laser 
scanning microscopy (CLSM). The nanoparticles were delivered into skin using 
dissolving microneedles. Linear unmixing technique allowed for simultaneous imaging 
of both AuNCs-GNPs and skin autofluorescence with accurate signal separation. This 
underlines the great potential of applying the developed system for better 
understanding of the behavior and fate of nanomaterials in tissue. Additionally, it 





Keywords: protein-stabilized gold nanoclusters, nanotechnology, drug delivery, 
theranostics, fluorescent enhancement 









Gold nanoclusters (AuNCs) have gained growing interest recently. This is attributed to their 
unique properties and their various potential applications including bioimaging, (1-4) 
biolabelling (5), sensing (3, 4, 6, 7), and therapy (8). Gold nanoclusters are composed of 
several up to tens of gold atoms giving rise to ultra-small sized structures of less than 
2 nm (9). Due to their small size, they demonstrate molecule-like properties having 
discrete valence electronic states drawing near the molecular orbitals (10, 11). They 
do not exhibit plasmon resonance compared to larger gold nanoparticles but rather 
they show fluorescence in the visible or the near-infrared light region (12). Among their 
unique properties, having long lifetime NIR fluorescence, high two-photon excitation 
and photostability alongside with biocompatibility (13) allow them to be attractive for 
imaging in tissue and in vivo (2). 
In addition to the quantum confinement effect, ligands play an important role in 
controlling the chemical and physical properties of AuNCs (14). They generally have a 
metal core-shell structure, stabilized by ligands forming staple-like motifs on the 
surface (10). Controlling the core size during synthesis of the nanoclusters allows to 
tune the emission wavelength and intensity (15). On the other hand, charge transfer or 
electron donation from the ligands active groups to the metal core greatly contributes 
in regulating the fluorescence properties (16, 17). Besides, ligands can stabilize the 
fluorescence of AuNCs against environmental conditions such as change of pH and 
temperature, etc (18). 
Proteins and peptides are attractive stabilizing, capping and templating agents for the 
synthesis of AuNCs. They offer essential attributes for the fabrication of metal 
nanoclusters such as the mild reaction environment, water solubility and 
biocompatibility (19), in addition to their biological, medicinal and pharmaceutical 
applications. Glutathione has been widely utilized for AuNCs synthesis (4, 20-24) due 
to the strong affinity of the thiol group to form Au-S bond (23, 25). Cysteine-containing 
proteins such as bovine serum albumin (BSA) (26-31), insulin (32, 33), trypsin (34, 35) 
and lysozyme (36, 37) have been also investigated for the same purpose. Other 
studies have also shown that basic amino acids together with tyrosine and tryptophan 
can contribute to the reduction of gold ions into atoms (38). In addition, the protein 








organizational structure can control the NCs’ properties, where amyloid fibril (cross-β-
sheet structures) formation can lead to red-shift in fluorescence (39). 
However, the mechanism of nanoclusters formation is still not fully understood. Careful 
selection of the suitable ligand is a prerequisite for optimizing and stabilizing the optical 
properties of the nanoclusters. On the other hand, establishing a correlation between 
the physicochemical properties of AuNCs to their structure is very crucial. This 
represents a step towards better understanding of the nanoclusters’ behaviour and 
easier properties’ manipulation to fulfill different applications. X-Ray Photoelectron 
Spectroscopy (XPS) can serve as a useful tool for investigating the effect of ligands on 
the atomic structure of AuNCs by studying the oxidation state of the elements forming 
the nanoclusters and the bonding properties as well (10, 27). 
Synthesis of AuNCs labelled-pharmaceutical proteins and polymers will pave the way 
and allow to obtain multifunctional nanoparticles (NPs) for simultaneous drug delivery 
and bioimaging and/or biosensing. Gelatin is a versatile carrier commonly used for the 
delivery of biomacromolecules and hydrophilic drugs (40) due to its hydrophilic nature, 
biodegradability and biocompatibility. The biocompatibility of the multifunctional NPs is 
essential; where AuNCs are easily excreted from the body, due to their small size less 
than the renal clearance cut-off, and gelatin NPs are degraded and solubilized. To our 
knowledge, gelatin has not been investigated yet for synthesis of fluorescent AuNCs, 
despite its widespread use in preparation of gold nanoparticles. We envisage that the 
gelatin-mediated synthesis of AuNCs could open the door for different pharmaceutical 
or biomedical applications. In this respect, we succeeded In using gelatin to synthesize 
NIR-emitting AuNCs. We have managed to control the fluorescence properties of the 
nanoclusters by varying the conditions of the reaction. AuNCs-modified gelatine has 
proven capable of forming nanocarriers (GNPs) with the ultimate goal of imaging in 
tissue. Such system can be of high potential for theranostics for simultaneous 
bioimaging and delivery of macromolecules as antigens. 
3.3. Materials and methods 
3.3.1. Materials 








Hydrogen tetrachloroaurate (III) trihydrate (HAuCl4.3H2O), gelatin type B (from bovine 
skin, gel strength ~75 g Bloom), silver nitrate, N-(3-dimethylaminopropyl)-N′-
ethylcarbodiimide hydrochloride (EDC), N-Hydroxysuccinimide (NHS), D-(+)- 
trehalose dihydrate, methanol, dimethyl sulfoxide were all purchased from Sigma 
Aldrich, Steinheim Germany. Ninhydrin (2,2-dihydroxyindane-1,3-dione) was 
purchased from Merck, Darmstadt, Germany. Trypsin from bovine pancreas (activity: 
3273.4 U/mg) was obtained from PanReac Applichem, Darmstadt, Germany. All 
chemicals were utilized without further purification. Milli-Q ultrapure water has been 
used for all experiments. 
3.3.2. Synthesis of gelatin-stabilized AuNCs 
 Gold nanoclusters stabilized by gelatin have been prepared by adding HAuCl4 to 
gelatin solution followed by adjusting the pH using 1N sodium hydroxide. The reaction 
has been carried out for 24h under vigorous mixing in a thermomixer (MHR, Hettich 
Benelux, Geldermalsen, The Netherlands) at 60 °C. Different HAuCl4 concentrations 
(1-20 mM) and different pH values (7-12) have been tested for AuNCs formation 
evaluated by fluorescence evolution. The optimized nanoclusters (Aug) have been 
utilized for further investigations. 
 
3.3.3. Synthesis of gelatin-stabilized AuNCs modified by glutathione 
 In one-pot reaction, glutathione (GSH) with different concentrations (5-25 mM) was 
added to 4% w/v gelatin, followed by addition of 10 mM HAuCl4.  All other settings were 
adjusted as shown before and the reaction proceeded for 24h. The optimized 
formulation (AuS) has been applied for further modifications as will be shown later. 
 
3.3.4. Gelatin structure integrity 
Selected formulations showing the highest fluorescence were repeated following the 
previously mentioned procedure while varying the reaction time (1 - 24h). The 
fluorescence at the maximum wavelength was plotted against time and further the 
samples were examined for gel formation after cooling to 4 °C.  The free amine groups 
in gelatin were quantified by ninhydrin test over different time intervals of interaction 
with gold. Briefly, pH of AuNCs-modified gelatin was adjusted to 7 by 1N HCl and mixed 








vigorously (1000 rpm) with 3% ninhydrin solution in 90 % DMSO at 80 °C for 5 minutes. 
Then, the mixture was cooled down to room temperature for 30 min and absorbance 
was measured at 575 nm. Calibration curve was constructed using glycine as a 
standard (41) following the same procedure. Fourier transform infrared spectrometry 
(FT-IR) and matrix-assisted laser desorption/ionization time of flight mass 
spectroscopy (MALDI-TOF MS) were performed. Freeze-dried samples of selected 
AuNCs-modified gelatin have been scanned for their FT-IR spectrum between 4000 
and 400 cm–1 (Spectrum 400, FT-IR/FT-NIR Spectrometer, PerkinElmer, Rodgau, 
Germany). For MALDI-TOF MS, samples were analysed in positive mode with a matrix 
of sinapinic acid using Applied Biosystems 4800 MALDI TOF/TOF analyzer (Applied 
Biosystems, Warrington, Cheshire, United Kingdom).  
 
3.3.5. Synthesis of Ag-modified AuNCs stabilized by gelatin and glutathione 
The GSH-modified gelatin stabilized AuNCs synthesized after optimized conditions 
(AuS) have been further modified using silver ions following two different protocols: (I) 
To form alloy metal NCs, AgNO3 has been added during the formation of the 
nanoclusters. Effect of different Ag/Au ratio, reaction time, pH and temperature has 
been tested. (II) To modify the surface of AuNCs, AgNO3 has been added after the 
synthesis of AuNCs. For screening, fluorescence spectra have been recorded for all 
tested formulations (550 - 850 nm) upon excitation at 368 nm using Microplate reader 
(Infinite M200, Tecan group Ltd, Männedorf, Switzerland). 
 
3.3.6. Characterization of selected AuNCs formulations 
Optical properties: 3D-Fluorescence spectra have been recorded using Jasco 
spectrofluorometer FP-6500 (JASCO) in 1 cm cuvette with excitation wavelengths 380-
650 nm and emission range 450-750 nm. Time-correlated single photon counting 
(TCSPC) measurements have been performed with a home-built setup. Excitation was 
done with a pulsed laser diode (PicoQuant, LDH-P-C-470, λ=470 nm; pulse width < 
100 ps) which was controlled by a diode laser driver unit (PDL 808 MC SEPIA, 
PicoQuant). After filtering through a band pass filter (685/70, AHF Analysentechnik), a 
single-photon avalanche detector (PDM 100ct SPAD, Micro Photon Devices) in 
combination with a photon counting device (PicoHarp 300, PicoQuant) was used for 








detection. To record the instrumental response function (IRF), a diluted colloidal silica 
solution (LUDOX TM-50, Sigma Aldrich) was used and the overall instrumental 
response function was 300 ps (FWHM). All fluorescence lifetimes were measured 
under magic angle conditions. The collected data was analysed using exponential fit 
functions (SymPhoTime, (PicoQuant) software). The fluorescence quantum yield was 
measured on an Absolute PL Quantum Yield Spectrometer C11347 (Hamamatsu) 
using an Ulbricht sphere in scan mode (emission range from 196 nm to 958 nm), using 
blanks prepared the same as the nanoclusters without Au or Ag addition as references. 
Fluorescence imaging has been carried out by confocal microscope (LSM 710, Zeiss, 
Jena, Germany) using excitation laser of 405 nm and emission was detected between 
600 - 740 nm.  
Transmission electron microscopy (TEM): Drop of AuNCs-modified GNPs has been 
loaded on a carbon-coated copper TEM grid. The drop was left to deposit on the grid 
for 45 s and then the excess was carefully removed with Kimtech© tissue. After drying, 
2% uranyl acetate solution was used to stain the sample for 45 s and again the excess 
liquid has been removed. Finally, the grid was let to dry for 2 min and subsequently 
washed using a drop of water for few seconds and then was let to dry completely. The 
samples were analyzed using JEOL JEM 2100 transmission electron microscope, 
operating at a maximum accelerating voltage of 250 kV. 
Robustness of AuNCs fluorescence against changes in environmental conditions (pH 
and enzymatic activity) has been tested. The emission at maximum wavelength was 
recorded upon excitation at 368 nm for the as prepared AuNCs and after pH change. 
On the other hand, AuNCs in PBS (pH 7.4, 5 mg/mL) were mixed with different 
concentrations of trypsin solutions at 500 rpm and 37° C for 15h. Fluorescence was 
recorded before and after reaction with trypsin.  
 
3.3.7. XPS analysis 
Samples’ pH was adjusted to 7, freeze dried and then analysed using a KAlpha+ 
spectrometer (ThermoFisher Scientific, East Grinstead, United Kingdom) equipped 
with a microfocused, monochromated Al Kα X-ray source (400 μm spot size). The 
charge compensation system was applied using electrons of 8 eV energy and low-
energy argon ions to prevent any localized charge build-up. The electrons’ kinetic 








energy was measured by a 180° hemispherical energy analyzer in the constant 
analyzer energy mode (CAE) at 50 eV pass energy. Data acquisition and processing 
using the Thermo Avantage software is described elsewhere (42). The Scofield 
sensitivity factors were applied for quantification (43). All spectra were referenced to 
the C 1s peak at 285.0 eV binding energy (C–C, C–H). 
 
3.3.8. Preparation and characterization of AuNCs-modified GNPs 
They were fabricated using two step desolvation method and crosslinking. For the first 
precipitation, methanol was added to the AuNCs-modified gelatin and shaken to 
precipitate the high molecular weight fractions and the turbid supernatant was 
discarded. The gel-like mass of gelatin has been freeze-dried, weighed and dissolved 
in water at 50 °C giving rise to 2% w/v solution. The pH of gelatin solution was adjusted 
to 8 using 1N NaOH and methanol was added dropwise while stirring until the first 
turbidity was observed indicating the formation of NPs. They were further crosslinked 
using a mixture of EDC/NHS that was added dropwise. The NPs dispersion was kept 
under stirring at 600 rpm for 18h. They were purified by centrifugation (Thermo Fisher 
Scientific, Osterode am Harz, Germany) at 20,000 g for 1h at 20 °C followed by 
washing that was repeated 3 times. Following, the NPs dispersion was freeze-dried 
using 3% w/v trehalose as a cryoprotectant to be further used for other experiments.  
Dynamic light scattering (DLS) measurements: Size and zeta potential of the as-
prepared nanoparticles were detected by Zetasizer (Nano ZS, Malvern Instruments 
Ltd, Malvern, UK) after appropriate dilution. 
 
3.3.9. Cell culture 
Human keratinocytes cell line (HaCaT) has been cultured in Dulbecco's Modified 
Eagle's Medium (DMEM) (Gibco®, Thermo Fischer Scientific, Paisley, United 
Kingdom) supplemented with 10% fetal calf serum and 100 U/ml penicillin–
streptomycin. The cells were incubated at 37 °C under 5% CO2. Cytotoxicity of the 
selected Ag-Au alloy NCs (AuAgS)-modified GNPs has been tested using MTT assay 
for cell viability. Cytotoxicity test. HaCat cells were cultured in Dulbecco’s modified 
Eagle’s medium supplemented with penicillin and streptomycin (100 U/mL) and 10 % 
v/v fetal bovine serum. They were seeded in a 96-well microplate (10,000 cells/well) 








and maintained in 5 % CO2 humidified incubator at 37 °C for 3 days. Then the medium 
was replaced with fresh medium containing AuAgS-GNPs (200 µL, 25-800 µg/ml). 
They were incubated with careful shaking for 24 h at 37 °C. MTT assay was carried 
out for the samples against negative control (treated with medium) and positive control 
(treated with 2% triton-X).  Media have been removed and the cells were washed with 
Hank's Balanced Salt Solution buffer (HBSS) and incubated with 3-(4,5-Dimethyl-2-
thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide (MTT reagent) for 4 h, followed by 
DMSO treatment. The absorbance of the formed formazan solution (OD) was 
measured at 550 nm using microplate reader and the cell viability % has been 
calculated. 
Cell viability % = 
(Sample OD − positive control OD)
(𝑛𝑒𝑔𝑎𝑡𝑖𝑣𝑒 𝑐𝑜𝑛𝑡𝑟𝑜𝑙  𝑂𝐷− 𝑝𝑜𝑠𝑖𝑡𝑖𝑣𝑒 𝑐𝑜𝑛𝑡𝑟𝑜𝑙 𝑂𝐷)
 𝑥 100 
 
3.3.10. Bioimaging of GNPs with skin tissue 
Excised human skin was obtained from abdominal plastic surgeries after the approval 
of the Research Ethic Committee of Saarland, Germany (Ärztekammer des 
Saarlandes, Dec. 2008) and permission of the volunteers. For skin preparation, the 
subcutaneous fatty tissue was removed and the skin surface has been cleaned by 
water. Skin samples were kept in aluminum foils and stored in -20°C to be used within 
no more than 6 months. For the imaging experiment, skin punches of 12 mm diameter 
have been cut and thawed and the surface was cleaned with water.   
Untreated human skin samples and AuAgS-modified GNPs were separately scanned 
for their emission spectrum in the range 600 - 740 nm by confocal microscopy using 
lambda mode upon excitation at 405 nm. The treated skin samples have been tested 
applying the same parameters. Two groups of skin samples were treated with AuAgS-
modified GNPs; a) by addition of NPs to skin surface and b) by insertion of AuAgS-
modified GNPs-loaded microneedles into skin. For the surface treatment, 20 µL of 
AuAugS-modified GNPs (3 mg/mL) was pipetted over the surface of the skin punch. 
For the microneedles (MNs) treatment, dissolving polyvinyl alcohol (PVA)/sucrose 
microneedles patch (1x1 cm) loaded with NPs was applied to skin and the lodged MNs 
were imaged within skin. The skin was kept moistened by placing it over a wet filter 
paper in a circular chamber to prevent skin drying during examination and avoid 








pressure application over the skin surface as described earlier by Stracke et al (44). 
The skin punch has been fixed on a microscopic slide with the skin surface facing 
upward that was covered by a cover slip to be examined by CLSM. A scheme of the 
experimental setup is shown in Figure S1 (Annex section). 
Using the linear unmixing algorithm available in the Zen Black© software, the 
fluorescence signal of the NPs were separated from that of skin. For depth profiling, 
objectives (LCI Plan-Neofluar 25x/0.8 Imm Korr DIC M27 and EC Plan-Neofluar 
10x/0.3 M27) have been used and z-stacks have been recorded with 5 and 10 µm 
steps for the surface and microneedles applications, respectively, and 3D images have 
been constructed. 
 
3.4. Results and Discussion 
3.4.1. Synthesis of gelatin-stabilized AuNCs 
Gelatin is a natural polymer, which consists of a mixture of proteins and polypeptides 
resulting from the hydrolysis of collagen. We used gelatin type B to sequester and 
reduce Au (III) to Au (0), which combine together to form AuNCs emitting fluorescence 
at λmax 640 nm. Different gold concentrations and pH values were tested to optimize 
the synthesis process. The fluorescence intensity increased with Au concentration up 
to 5 mM, while further increase in concentration resulted in gradual loss of fluorescence 
(Figure 1A, Figure S2 (Annex section)). The latter can be attributed to the formation of 
quenching larger gold nanoparticles, which affect the fluorescence negatively (45). At 
a concentration of 30 mM gold chloride, only gold nanoparticles have been produced 
as observed by TEM (Figure S3A (Annex section)). On the other hand, pH adjustment 
was essential to initiate the reaction between gold and gelatin. At pH range (7-12), the 
fluorescence increased with pH to be maximized at pH 12 (Figure 1B). Among the 
amino acids composing gelatin, the basic amino acids; arginine (8%) (46) and lysine 
(4%) (46), have the ability to reduce Au (III) ions to Au (0) by electron transfer from the 
side chain amines. According to Xu et al, arginine and lysine can form complexes with 
Au (III) that can be further reduced by tyrosine under alkaline conditions (38), but 
tyrosine represents only <0.5% of gelatin weight (46). On the other hand, glutamic acid 
(10%) (46) may contribute to the thermal reduction of gold ions (47). All these 
mechanisms can variably contribute to the formation of AuNCs. 



















Figure 1. Gold nanolcusters stabilized by gelatin only; A) Effect of gold molar concentration 
and B) Effect of pH on the maximum emission fluorescence at 640 nm. Gold nanoclusters 
stabilized by gelatin and glutathione (GSH); C) Effect of GSH concentration on the 
fluorescence of AuNCs at 690 nm, when used alone (Au-GSH) and in combination with gelatin 
(AugB-GSH) and D) Effect of pH on the maximum emission of the gelatin-GSH-stabilized 
AuNC fluorescence at 690 nm. AugB-GSH describes nanoclusters stabilized using gelatin and 
different concentrations of glutathione. Au-GSH is the clusters stabilized with different 
concentrations of glutathione only without using gelatin. For all experiments; mean ± SD, n=3. 
 
The polymer backbone structure and viscosity play a role in controlling the growth rate 
and the stabilization of AuNCs. Compared to gelatin A, gelatin B showed better 
efficiency in forming fluorescent AuNCs (Figure S4A (Annex section)). This can be due 
to the content of glutamic acid in gelatin B, which results by the alkaline hydrolysis of 
collagen (48). In addition, gelatin B is expected to have more free amines due to the 
lower isoelectric point (4-6) compared with 7-9 in gelatin A (49). On the other hand, 
higher bloom of gelatin B (225 g) resulted in less fluorescence compared to bloom 75 
g (Figure S4B (Annex section)), which might be due to the higher flexibility of short 
polymer chains to interact with gold ions. Although the viscosity contributes to the 
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stability of AuNCs, the excessively increased viscosity may reduce the electron 
transfer to Au ions, resulting in lower rate of reduction (50). For up-scaling the AuNCs 
production, multiples of gelatin concentrations have been tested while multiplying the 










Figure 2. A) Effect of GSH addition and the change of pH on the reaction rate for the formation 
of gelatin-stabilized AuNCs, represented by fluorescence intensity (mean ± SD, n=3). The 
different reaction conditions; 4% w/v gelatin at pH 12 (AugB / pH 12), 4% w/v gelatin and 10 
mM GSH at pH 12 (AugB-GSH / pH 12) and 4% w/v gelatin and 10 mM GSH at pH 11 (AugB-
GSH / pH 11), B) Quantification of the free amine groups of gelatin after different reaction times 
with gold chloride at pH 12 (AugB / pH 12) using ninhydrin test (mean ± SD, n=3). AugB 
represents nanoclusters stabilized by gelatine at different pH and reaction time.  
 
Glutathione (GSH) is an effective reducing agent commonly used to prepare AuNCs 
due to the presence of thiol group. One-pot synthesis of AuNCs using gelatin and 
various glutathione concentrations allowed to tune the emission spectrum of the 
nanoclusters (Figure S6 (Annex section)). The selected 10 mM GSH concentration 
resulted in 50 nm red-shift in the AuNCs fluorescence (λem = 690 nm). Interestingly, 
under the tested reaction conditions, GSH alone, with the same concentration, was not 
capable of forming fluorescent AuNCs. Only GSH of 15 mM concentration resulted in 
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detectable fluorescence when reacted with gold chloride, which was even enhanced 
by the addition of gelatin (Figure 1C). This proves that gelatin and GSH have a 
synergistic contribution to the formation of AuNCs. Ligand modification and thus the 
introduction of more electron-rich functional groups, can manipulate the electron 
transfer to the metal core, and consequently influence the fluorescent properties of 
AuNCs (16). Furthermore, increasing the pH from 7 to 12 resulted in gradual increase 
in fluorescence (Figure 1D). 
3.4.2. Structure integrity of gelatin during AuNCs formation 
To further use the gelatin for pharmaceutical applications, a compromise between the 
AuNCs formation and maintaining the polymer integrity is necessary. Controlling the 
pH has the ability to manipulate the reaction rate (Figure 2A). At the same time, it 
affects the gelatin structure particularly at high temperatures. At pH 12 and after 6h of 
the reaction with gold ions, gelatin has lost its gelling properties upon cooling to 4 °C. 
Conversely, pH 11 preserves the polymer’s gelation capabilities till reaction is 
completed after 24h (Figure S7 (Annex section)). In order to further investigate the 
gelatin structure, ninhydrin test was performed to quantify the free amine groups at 
different time intervals of the interaction with gold. After 1h of reaction at pH 12, the 
free amino groups were reduced to 87% and this can be attributed to the coordination 
established between –NH2 and Au. The percentage increased to 94 after 3h, 
continuing gradually to hit 145% after 24h of the reaction, suggesting gelatin 
degradation and hence the rise of free amine groups of the polypeptide (Figure 2B).  
 
Two AuNCs formulations have been selected, so far, for further studies: AuNCs 
synthesized by gelatin at pH 12 and 3h of reaction and the other formulation was 
prepared by gelatin and GSH at pH 11 for 24h (AuS) (Table S1). These formulations 
showed well detectable fluorescence by confocal microscopy upon excitation at 405 
nm (Figure S8B (Annex section)). They have been examined as well by FT-IR and 
MALDI-TOF MS to show differences in gelatin structure as opposed to untreated 
polymer. MALDI-TOF MS is a common tool for studying the core size of AuNCs and 
composition of ligand. Nonetheless, calculating the AuNCs core size by detecting the 
number of gold atoms in such a case was not an accessible option due to the 








heterogeneous mass of the gelatin polypeptides mixture, in addition to the potential 
fragmentation of the nanoclusters during ionization (27, 51). In parallel, the 
examination of the change in the mass spectrum of gelatin could be determined. Figure 
3A shows the mass spectra of gelatin and both formulations of the nanocluster: Aug 
and AuS. Peaks of lower molecular weight (m/z ≈ 3100) appear in both Aug and AuS. 
The two spectra display different regions of approximately the same m/z ratio as the 
untreated gelatin, with variable peak intensities. Using the stated conditions for Aug 
and AuS synthesis, controlled gelatin degradation while retaining the gelling properties 


















Figure 3. Investigating the effect of AuNCs on the gelatin structure by comparing AuS and Aug 
to untreated gelatin A) MALDI-TOF MS spectra recorded in the positive modes show areas of 
similar mass (m/z), B) FT-IR spectra showed a negligible shift in amide I from 1629 cm-1 for 
gelatin to 1632 in both Aug and AuS indicating β-sheets secondary structure (1623 – 1641 cm–
1) for all of them. Aug is the optimized formulation of gelatin-stabilized nanoclusters with 
reaction time of 3h / pH 12. AuS represents the optimized formulation using gelatin and 












On the other hand, FT-IR is commonly used to investigate the conformational changes 
of proteins and peptides, particularly in the secondary structure. Amide I (1600 – 1700 
cm–1, mainly due to CO stretching vibration) and amide II (≈1550 cm–1, NH bending 
and CN stretching vibration) are characteristic bands for the secondary structure. 
However, is less straightforward to correlate the secondary structure to amide II than 
amide I (52). Untreated gelatin showed amide I band at 1629 cm–1 (Figure 3B) 
revealing β-sheets secondary structure (indicated by amide I in the range 1623 – 1641 
cm–1) (52). A very small shift to 1632 cm–1 after the reaction with gold (in Aug and 
AuS) indicates no or minimal changes in the secondary structure. By controlling the 
pH and the reaction time, we managed to preserve the structural and conformational 
integrity of gelatin, to be further used for NPs fabrication. 
 
3.4.3. Fluorescence enhancement 
Enhancing the fluorescence will be crucial for different bioimaging purposes, 
particularly in tissues. One strategy to enhance the fluorescence intensity is the 
formation of alloy nanoclusters, by doping another noble metal during the nanoclusters 
growth. Silver and gold have been considered as a common combination for fabrication 
of alloy nanoclusters (53, 54). Modification of gold nanoclusters by silver has been 
reported to enhance the emission (53, 55). It was important to optimize the Ag : Au 
molar ratio (0.4) to obtain the highest possible fluorescence intensity, while using 
gelatin and GSH as ligands (Figure S9 (Annex section)). Surprisingly, doping of Ag 
ions after 6 h from the start of the reaction resulted in 2.5 fold increase in fluorescence 
rather than addition at the start of the reaction (Figure S9 (Annex section)). This might 
indicates the significance of the different arrangements of noble atoms in the core to 
control the fluorescence properties of the alloy nanoclusters. In another strategy, we 
investigated the addition of Ag ions after the reaction of AuS formulation was 
completed. Adjustments of the Ag: Au molar ratio, pH and reaction time were 
considered to maximize the intensity of the fluorescence (Figure S10 (Annex section)). 
Eventually, two Ag-modified formulations; alloy AuNCs (AuAgS) and post-synthesis 
Ag-modified AuS (AuS+Ag) as shown in table S1 were selected for further 
characterization in comparison to Aug and AuS. TEM images and measured size 








distributions are shown in Figures S11 and S8 (Annex section) of silver-modified and 
pure gold nanoclusters, respectively. 
 
Figure 4A shows the 3D emission spectra of the four selected formulations. All samples 
showed broad emission spectra. Red-shift in the fluorescence maximum wavelength 
was observed due to the co-stabilization with GSH and enhancement of fluorescence 

















Figure 4. Optical properties of different AuNCs; Aug, AuS, AuAgS and AuS+Ag, A) 3D 
emission spectra at excitation wavelength range 380-650 nm and the emission was recorded 
from 450 to 750 nm, B) Averaged lifetime (measured upon excitation at 470 nm) correlation to 
averaged absolute quantum yield % (measured upon excitation at 400-550 nm with 5 nm 
steps). The fluorescence around 450-550 nm is due to the gelatin autofluorescence. 
 
 
Both alloy nanoclusters formation and post-synthesis modification by Ag resulted in 
enhanced broad red emission bands upon excitation at 380-550 nm. This offers a 
variety for the nanoclusters application for bioimaging over a wide range of 
fluorescence imaging settings. Absolute quantum yields (QY) were measured using 
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integrating sphere setup at different excitation wavelengths (400-550 nm) and were 
corrected for the blue fluorescence of gelatin (Figure S12A (Annex section)). 
Modification with Ag resulted in an approximate 3-fold increase in the QY upon 
excitation at 400 nm compared to AuS. The measurements revealed that Ag-modified 
AuNCs have an excitation wavelength- dependent QY and this behavior is more 
pronounced in AuAgS. They showed maximum QY at 400 nm (24 %) that declined to 
reach the value of AuS (~ 9%) at 500–550 nm (Figure S12 (Annex section)). 
Nevertheless, modification by Ag resulted in lower rate of fluorescence decay when 
excited at 470 nm (Figure S12B (Annex section)). Interestingly, it turns out that the 
enhancement of QY after the addition of Ag is correlated with an extended 
fluorescence lifetime, as summarized in figure 4B. 
 
3.4.4. Structure - fluorescence stability relationship 
Examination of the different AuNCs by XPS provided valuable insight on the oxidation 
state of the metal elements providing information about the core-shell structure of the 
nanoclusters. This opens the venue for a better understanding of the nanoclusters 
formation and further correlation to their optical properties and photostability. Starting 
with Aug, Au 4f doublet can be deconvoluted into 3 distinct components with Au 4f7/2 
at 84.3, 85.3 and 87.6 eV referring to Au (0), Au (I) and Au (III), respectively (56) (Figure 
5). So, after 3h of reaction with gelatin at 60 °C under alkaline conditions, Au (III) has 
been reduced partially to Au (I) and Au (0) to form AuNCs. However, Au (III)-protein 
complex has been assigned recently by Dixon and Egusa to also contribute to the 
fluorescence (57). By virtue to the electron-donating groups in gelatin, Au (I) as an 
intermediate reduced state of gold has been produced, with a further reduction to Au 
(0). The aggregation of Au (0) results in the formation of a metal core with Au (I) on the 
surface as the nanoclusters’ shell as a typical structure defined in literature (11, 27, 
58). After 24h of reaction, all Au (III) has been totally reduced to Au (I) and Au (0) 
(Figure 5A). On the other hand, co-reduction with GSH resulted in complete reduction 
to Au (0) forming two populations of AuNCs of different core sizes with Au 4f7/2 peaks 
of Au (0) at 83.9 and 84.6 eV (Figure 5B). As reported earlier, the higher binding energy 
of Au (0) indicates an increase in the core size (27). Addition of Ag ions after the 
formation of AuS resulted in no change in the Au oxidation state with Au (0) peaks at 








84.2 and 84.9 eV. Possibly, Ag ions are further reduced by the ligands and 
incorporated in or replaced some of the Au atoms at the surface of the nanoclusters. 
Another technique such as X-ray powder diffraction (XRD) (55) is required to confirm 
the atoms arrangement within the clusters, but this was not possible due to the very 
minute amount of Ag and Au compared to the gelatin in the current formulations matrix. 
Similarly, complete reduction of Au was observed with the formation of alloy NCs 
(AuAgS), but interestingly with homogenous-sized population of AuNCs (Au 4f7/2 
showed one peak at 84.5 eV) (Figure 5B). However, we cannot provide any evidence 
of Ag reduction particularly with the difficulty to distinguish between Ag 3d5/2 
corresponding to Ag (0) and Ag (I) without Auger lines analysis, which was hampered 
by the very low concentration of Ag (Figure S13 (Annex section)); almost the detection 
limit. Co-reduction with GSH showed S 2p doublet with S 2p3/2 at 161.8 eV (S-Au; S-
Ag if present) (59), 163.8 eV (S-H), 166.2 eV (oxidized sulfur: S (IV)) and 168.6 eV 
(oxidized sulfur: S (VI) (60) (Figure 5C) with very weak concentrations of 0.02, 0.03, 
0.09 and 0.05 at % in AuAgS, respectively. A potential Au-S bond may be formed; 
however data must be taken with caution due to the very low concentration of these 
elements compared to the bulk of the sample which constitutes out of gelatin, and the 
detection limit of the method. But on the other hand, the concentrations of Au and Ag 
were found within the same range with values of 0.02 and 0.01 atomic % respectively, 
which supports the assumption of formed Au-S and eventually Ag-S bonds. 
 
The structure of AuNCs together with the ligand plays the major role in controlling their 
optical properties due to the transfer of electrons between the ligand and the metal 
surface and within the metal core. On the other hand, ligands as capping agents control 
the fluorescence stability of AuNCs in response to the different environmental 
conditions. In comparison to the original synthesis environment, testing the robustness 
of AuNCs fluorescence over a pH range (1.5 - 7), showed different degrees of stability 
arranged in the following order Aug < AuS < AuAgS < AuS+Ag (Figure 6A). However, 
all AuNCs showed considerable fluorescence stability at physiological pH; 
modifications with GSH and Ag have widened the pH stability range down to acidic 
conditions. Possessing the capability to manipulate the pH-response of AuNCs 
provides the opportunity for various applications. For instance, the pH-responsiveness 





















Figure 5. XPS spectra: A) Au 4f of AuNCs stabilized by gelatin at different reaction times (3 
and 24h), B) Au 4f of AuNCs stabilized by gelatin and glutathione (AuS, AuS+Ag and AuAgS 
from lower to upper panel). Yellow curve: Au (0) at 84.1 ± 0.2 eV, Purple curve: Au (0) at 84.7 
± 0.2   eV, Orange: Au (I) at 85.5 ± 0.2 eV, Green: Au (III), C) S 2p3/2 of different AuNCs (Aug, 
AuS, AuS+Ag and AuAgS from lower to upper panel). Magenta-filled: 161.8 eV (S-Au; S-Ag if 
present), Black: 163.8 eV (S-H), Violet: 166.3 eV (oxidized sulfur: S (IV)), Orange: 168.6 eV 
(oxidized sulfur: S (VI)). 
 
 
To investigate the contribution of gelatin and GSH in stabilizing AuNCs, a trypsination 
experiment has been performed. Trypsin specifically works by hydrolyzing the peptide 
bonds on the carboxylic terminal of lysines and arginines. The degree of hydrolysis 
varies depending on the trypsin concentration and the amino acid sequence of the 
protein (62). In case of Aug, gelatin is the main reducing and capping agent of AuNCs. 
Gelatin fragmentation by trypsin resulted in decrease of the fluorescence that was 
trypsin-concentration dependent as shown in figure 6C. When the polypeptide loses 
the integrity of its structure, which was responsible for holding the gold atoms and ions 
together, they dissociate and the fluorescence diminishes as observed at trypsin 
activity of 3.2 x 103 U/mg of gelatin. Interestingly, AuS fluorescence showed much 
higher stability to trypsin digestion. It can be envisaged that even after gelatin digestion, 
the AuNCs structure is still preserved by binding to the thiolate groups of GSH and 
fractions of degraded gelatin. This provides valuable information regarding the role of 
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both gelatin and GSH in AuNCs protection. When AuAgS showed intermediate stability 
to gelatin, AuS+Ag demonstrated ultimate stability (Figure 6B). The latter even showed 
a slight increase in the fluorescence, probably due to the adsorption of trypsin to the 
AuNCs (63-65). This formulation will be interesting for long-term imaging of AuNCs in 
tissues due to their stability independent of the integrity of gelatin as a capping agent. 
On the other hand, AuAgS would be beneficial for mechanistic studies, especially when 
formulated as GNPs. Their bright fluorescence together with their intermediate 
sensitivity to polymer degradation will be a beneficial option to smartly track the NPs 
and follow their fate in tissues. In conclude, NCs can offer stimuli-responsive 
fluorescence i.e. smart probes (different response to pH, enzymatic degradation, etc), 
which can be controlled by manipulating the composition of NCs and ligands. This is 
an advantage of such imaging probes over regular dyes, where different stimuli-
responsiveness require careful selection of more than one dye to perform the same 
functions. 
 
From the knowledge gained throughout the characterization of the different AuNCs’ 
optical properties and XPS studies implemented in this research work, together with 
literature knowledge on the general structure of gold nanoclusters (11, 13, 58), 
simplified models for the nanoclusters were proposed as shown in figure 6C. Aug, 
where nanoclusters are produced only using gelatin, is considered to be the parent 
formulation, which is further modified into other formulations with different properties. 
These clusters exhibited a typical core-shell structure composed of Au (0) and Au (I) 
protected by gelatin as the only ligand. Further, the introduction of GSH resulted in 
complete reduction of Au (III) to Au (0) and nanoclusters formation of two different 
sizes. In addition, stabilization by GSH offered greater protection of the nanoclusters 
fluorescence against pH change and enzymatic degradation. Addition of Ag ions after 
or during the synthesis of AuS resulted in increased fluorescence intensity, QY, 
lifetime, and stability. Addition of Ag after the synthesis of AuS (AuS+Ag) led to no 
changes in the oxidation state of Au and some incorporation of Ag into the nanoclusters 
surface. On the other hand, addition of Ag ions during the synthesis process of AuS 
appears to lead to the formation of smaller alloy nanoclusters (AuAgS) but of 
homogenous size. 





































Figure 6. Fluorescence stability  of different AuNCs to; A)  pH changes by changing the pH 
from that of synthesis to lower pH values (1.5 -7) (mean ± SD, n=3), B)  gelatin digestion using 
different concentrations of trypsin at pH 7.4, 37 °C for 15h. Fluorescence intensity was 
recorded at λmax for the different AuNCs (640 nm for Aug, 690 nm for AuS and 700 nm for both 
AuS+Ag and AuAgS) (mean ± SD, n=3). This shows the effect of GSH and Ag ion addition on 
enhancing the AuNCs fluorescence stability against pH changes and trypsinisation C) 
Simplified proposed models for AuNCs structure based on XPS data. Aug: showed a typical 
core-shell structure of Au (0) and Au (I) respectively. For all others GSH-modified AuNCs, Au 
(0) was the only oxidation state with Au-S bonding. The AuNCs have different core size (the 















3.4.5. Formation of protein nanoparticles using AuNCs-modified gelatin 
Such NPs were prepared from AuNCs-modified gelatin, using two-step desolvation 
method. Desolvation is the dehydration of gelatin by adding an antisolvent, which 
results in coiling of the polypeptide chains. The first desolvation step was to separate 
the gelatin fractions of high molecular weight (HMW). Discarding the low molecular 
weight fractions (LMW) of gelatin will improve the homogeneity of the NPs size and 
prevent irreversible aggregation (66). The redissolved HMW gelatin was again 
desolved to form NPs that were further cross-linked to preserve their conformation in 
aqueous environment. Various parameters have been optimized such as the 
antisolvent, the pH of gelatin solution and the crosslinking agent.  
 
NPs formation is a complex phenomenon controlled by the polymer-antisolvent-solvent 
system. The antisolvent’s diffusion and affinity to solvent and the polymer-solvent 
interactions influence the particle size (67). Of the various organic solvents (acetone, 
acetonitrile, isopropanol, ethanol) only methanol was suitable for the formation of 
AuNCs-modified GNPs. At the first desolvation step, the pH of gelatin solution was 
adjusted to 7 to balance between preserving the fluorescence of AuAgS and reducing 
the gelatin charge to induce precipitation, while at the second desolvation, the pH was 
adjusted to 8 to prevent aggregation of the NPs. For crosslinking, glutaraldehyde, 
which is a common crosslinker for GNPs, resulted in complete loss of the Aug-modified 
GNPs fluorescence, which comes in agreement with a previous report by Khandelia et 
al. (68). This can be attributed to the crosslinking mechanism of glutaraldehyde which 
is a non-zero length crosslinker that connects the alpha-amino groups of lysine 
residues (69). As a result, another crosslinker has been applied to preserve the 
fluorescence. This was a mixture of N-(3-Dimethylaminopropyl)-N′-ethylcarbodiimide 
hydrochloride (EDC) and N-Hydroxysuccinimide (NHS); a zero-length crosslinking 
agent that couples carboxylic to primary amine groups (70). 
 
Nanoparticles of narrow particle size distribution have been produced using Aug, AuS 
(Figure S14 (Annex section)) and AuAgS-modified gelatin (Figure 7A). TEM showed 
that the NPs are spherical in shape and non-aggregated and revealed the internal 
distribution of the AuNCs. Among them, AuAgS-GNPs were of interest for further 








studies with Z-average size of 218.8 + 1.7 nm and a size distribution represented by 
the polydispersity index (PDI) of 0.073 + 0.016. They showed high colloidal stability 
and further freeze drying with trehalose had no effect on the particle size following 
redispersion. The NPs formation retained the fluorescence emission spectrum of 
AuAgS (Figure 7B). Absolute QY was measured (λmax = 400 - 550 nm) and corrected 
for the NPs scattering using a reference of similar plain GNPs. They showed an 
average QY of 14.8 + 0.8 % which was independent of the excitation wavelength, in 
contrast to the free nanoclusters. However, the formation of NPs have not changed the 
fluorescence lifetime behaviour, as AuAgS-GNPs showed higher fluorescence lifetime 












Figure 7. A) TEM image of AuAgS-GNPs with accelerating voltage 100 kV, B) Emission 
spectrum of the nanoparticles by excitation at 368 nm, C) Cytotoxicity testing of AuAgS-GNPs 
against human keratinocytes (HaCat cells) using different concentrations (25 - 800 µg/mL) by 




The cytotoxicity of AuAgS-GNPs has been tested against human keratinocytes (HaCat 
cell line) after 24h of incubation, using MTT assay, which assesses the cell metabolic 
activity. The NPs showed no cytotoxicity (≈ 100 % viability) at concentrations as high 
as 600 μg/mL (Figure 7C). This can be attributed to the biocompatibility of the materials 
used in the preparation including the non-toxic crosslinking agent (EDC). Concerns 
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over the reported toxicity of silver ions have been considered. Nevertheless, due to the 
very minute amount used in the formulation, and the possible complete reduction of 
Ag ions during the nanoclusters preparation, the formulation was biocompatible. 
Finally, the produced fluorescent GNPs are safe biomaterials that pave the way for 
various biological applications including drug delivery. 
 
3.4.6. Tissue bioimaging based on linear unmixing 
Imaging and tracking of NPs in tissue using confocal microscopy is a complex, even 
though beneficial process, which provides deeper knowledge about the efficiency and 
fate of nano-pharmaceuticals. In this regard, we have selected human skin to test the 
ability of our developed AuAgS-labelled GNPs to be imaged with tissue. Skin is 
regarded as a challenging tissue for imaging due to its density and auto-fluorescence 
that limits the process of suitable dyes selection. The capability of imaging 
nanoparticles with skin opens the avenue for better understanding of NPs behaviour 
in skin. This will be helpful for therapeutic purposes through transdermal drug delivery 
which gains a lot of attention recently to take over the invasive methods of drug 
delivery. On the other hand, occupational skin exposure to nanomaterials can be 
hazardous for human health, especially over a long term. Overall, the developed 
fluorescent GNPs can be further applied to different biological applications that can 
even extend from skin to other tissues. 
 
There are many endogenous auto-fluorescent substances in skin that may interfere 
with the analysis of various fluorophores. This makes the choice of an appropriate 
fluorophore, with a distinct fluorescence from that of skin, not an easy option, especially 
with the broad emission spectrum of skin. Even with suitable dyes, offsetting the skin’s 
fluorescence was the solution used by variant research groups for imaging of NPs in 
skin (71-74). However, the ability to image NPs together with skin structure will give 
visual evidence about the NPs penetration within the tissue. In this regard, others resort 
to either dual-channel imaging followed by subsequent images overlapping (75), or 
staining of skin prior to NPs examination (76). AuAgS-GNPs showed well-detected 
fluorescence in the red region of the spectrum (Figure 8A). This can be considered as 
the optimum properties of a fluorophore for imaging with skin. However, imaging of 








both NPs and skin simultaneously will be a more descriptive and time-saving method 
of analysis. 
 
Linear unmixing is a technique used to distinguish the signals of fluorophores of 
overlapping spectra. An algorithm is used to analyse each pixel and isolate the mixed 
fluorescence signals arising from multiple fluorophores into individual components 
accrediting to spectral reference fingerprints (77). AuAgS-GNPs showed a distinct 
fluorescence signal from that of skin (Figure 8A). Instead of canceling the skin 
fluorescence, linear unmixing was used to separate NPs from skin signal. To test the 
accuracy of the method, NPs have been added to the skin surface and imaged directly. 
Figure 8B shows ~ 200 µm depth profiling (z-stacks steps of 5 µm) of the NPs and 
skin, while 3D-constructed images are shown in Figure 8C. The images showed the 
NPs filling the furrows of the skin between the keratinocytes isles in a similar pattern 
to findings reported earlier by Stracke et al. (44). This indicates the applicability of the 
approach for accurately separating the signals, so penetration studies within the tissue 
can be further analysed.  
 
Microneedles have been commonly used as a minimally invasive mechanical 
penetration method to deliver biotherapeutics through skin (78). The nanocarriers 
labelled with NCs were loaded in dissolving microneedles consisting of PVA/sucrose. 
After microneedles insertion in skin, linear umixing showed the NPs distribution within 
the skin tissue with a depth profile of 760 µm (Figure 8D). So, spectral imaging with 
linear unmixing provide a time-saving, non-invasive and depth-revealing technique for 
simultaneous examination of the NPs and skin, which helps to avoid the artifacts 
produced during skin sectioning and staining. Finally, the developed AuNCs-modified 
GNPs showed to be an effective fluorescent probe for bioimaging with biological tissue 
such as skin. The developed nanoparticlulate system with assistance of a minimally 
invasive technique such as microneedles application, will be further investigated for 
delivering antigen through skin for transcutaneous vaccination with the ability of 
simultaneous biomaging and particles tracking. 
 
 






































Figure 8. A) Emission spectra of skin and AuAgS-GNPs recorded by confocal microscopy at 
λex 405 nm, B), C) 3D confocal imaging of NPs applied to the skin surface; B) z-stacks starting 












the furrows between the keratinocytes isles (green). The fluorescence channels were 
separated from the crude fluorescence using linear unmixing algorithm with reference to the 
fluorescence spectra of skin and NPs, C) 3D- images constructed from the z-stacks showing 
upper, lower and side view (from left to right) of the scanned area, D) 3D confocal imaging of 
NPs-loaded microneedles applied into skin, constructed from z-stacks recorded over 760 µm 
depth with 10 µm steps , showing the NPs (red) penetration depth (Zx and Zy) into skin tissue 





We proved the effectiveness of gelatin to produce fluorescent AuNCs, introducing 
different methods for tuning the emission wavelength alongside with the fluorescence 
intensity. Gold ions reduction-assisted by GSH, in one-pot synthesis, induced 50 nm-
red shift in the nanoclusters emission alongside with stabilization against pH changes 
and enzymatic degradation. Modification by Ag ions either by doping during or post the 
nanoclusters formation resulted in enhancement of the QY and fluorescence lifetime. 
Finally as a result, four different AuNCs have been produced, showing variant stability 
in response to pH and enzymatic degradation, so they can be acclaimed for various 
biological applications. The optical properties-structure relationship has been 
established with the aid of XPS analysis. Model-structures for the different 4 formulated 
AuNCs have been constructed, summarizing the effect of different modifications. On 
the other hand, optimization of the synthesis process resulted in preserving the gelatin 
structure integrity, to be further efficiently used for the preparation of GNPs. The NPs 
of size 218 nm showed distinct inner distribution of the AuNCs when examined by 
TEM. They preserved the fluorescence properties of the nanoclusters, thanks to the 
careful selection of the crosslinking agent (EDC/NHS). They showed biocompatibility 
toward human keratinocytes cell line up to 600µg/mL, which acclaims them for further 
applications in drug delivery. They have been imaged simultaneously with skin 
fluorescence using non-invasive time-saving method by combining CLSM and linear 
unmixing achieving a depth profile of 760 µm. Finally, our study can be considered as 
a platform for putting insights into the design, optimization and better understanding of 
the AuNCs formation and properties. The development of AuNCs-modified GNPs 
represents a very promising approach for imaging in a challenging tissue as skin that 








can extend to various theranostic and pharmaceutical applications, preferably antigen 
delivery for transcutaneous vaccination. 
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4. Customized Fast-Separable Microneedles Prepared with the Aid of 
3D Printing for Nanoparticle Delivery 
 
4.1. Abstract 
3D printing of master molds for soft lithography-based fabrication of microneedles 
(MNs) is a cost effective, easy and fast method for producing MNs with variable 
designs. Deviating from the classical geometries of MNs, ‘tanto blade’-inspired MNs 
showed effective skin penetration, acting as sharp structures with low insertion force 
of 10.6 N, which is sufficient for manual insertion. Additionally, hydrophilic, fluorescent 
noble metal nanocluster-modified gelatin nanocarriers were loaded in polyvinyl 
alcohol/sucrose MNs to act as a novel theranostic system emitting light in the near-
infrared (λ em = ~700 nm). Nanoparticles (NPs) distribution within the MNs and release 
have been monitored using confocal laser scanning microscopy by means of spectral 
analysis and linear unmixing. Furthermore, MNs patch was modified by carving a 
channel at each of the four corners of the patch. This facilitated the separation process 
of MNs from the patch base into skin, when a 15 µL of phosphate buffer saline was 
applied through each channel post-skin insertion of the MNs. Then, the patch base can 
be removed easily leaving the implanted MNs inside the skin for further release of the 
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Transdermal drug delivery is an attractive route to bypass the first pass effect that can 
hinder the effectiveness of many drugs (1). On the other hand, skin is an immune cell-
rich organ, such as Langerhans and dermal dendritic cells, which renders it an 
attractive pathway for vaccination (2). However, stratum corneum (SC), as the 
outermost layer of skin, represents a barrier against effective drug delivery through 
skin (3, 4). Among the strategies that have been introduced recently to overcome the 
SC barrier for drug delivery, microneedles (MNs) seem to be a very promising 
approach. These micro-structures are minimally invasive and a pain-free method to 
allow drugs and macromolecules bypass the SC and diffuse toward viable skin (5).  
 
Micromolding or soft lithography is the most common method for the fabrication of 
MNs. The process starts with the fabrication of a positive master mold that is utilized 
for the preparation of a negative replica. The latter is usually made out of 
polydimethylsiloxane (PDMS) and can be repeatedly used for the casting of MNs. This 
method is characterized by controlling the reproducibility of MNs’ shape and size (6). 
Different techniques have been assigned for the preparation of the positive master as 
photolithography (7), two-photon polymerization (8) and bulk micromachining (9). 
However, these techniques are complicated as well as expensive and can ultimately hinder 
the easy manipulation of the MNs’ designs. Controlling the shape and dimensions (aspect 
ratio and tip’s radius and angle) of MNs is crucial to manage their effectiveness. These 
parameters together with the polymers’ physical properties affect the mechanical strength 
and the insertion force and depth of the MNs (10, 11). Computer-aided additive 
manufacturing (‘3D printing’) can serve as a simple and cost-effective method for the 
fabrication of MNs masters with different designs. The ability to optimize the designs of the 
MNs, and thus obtain the best features in order to fulfill specific requirements, together with 
the ability to fabricate MNs from different polymers, is highly advantageous. Hence, more 
customized designs deviating from the traditional shapes (pyramidal, conical etc.) can be 
realized and tested.  
 
Dissolving MNs are composed of water-soluble polymers that dissolve and release the 
bioactives, leaving less environmental waste behind. They can effectively penetrate 








skin with relatively low insertion forces. Combining dissolving MNs with bioactives-
loaded nanoparticles (NPs) offers the advantage of controlling the release rate rather 
than having one bolus dose (5). In this regard, while designing the MNs and selecting 
the polymers, several aspects should be considered sequentially; 1) the MNs need to 
be robust enough to be inserted into skin, and then 2) separate fast from the patch 
base and solubilize in the interstitial fluid of the skin to 3) release the NPs which carry 
the medical cargo and control it’s delivery into the skin. 
 
Herein, we initiated a cost-effective fabrication sequence of MNs in the lab starting 
from building a master mold using 3D printing and ending with NPs-loaded dissolving 
MNs as the final product. Among various possible designs, we have selected a ‘tanto 
blade’-inspired design to enhance the insertion-ability of the MNs into skin. 
Nanoparticles synthesized from noble metals nanoclusters-labelled gelatin serve as a 
fluorescent probe (12) for imaging the MNs dissolution in vitro and their behavior inside 
excised human skin. A mixture of poly (vinyl alcohol) (PVA) and sucrose was used for 
the preparation of the MNs matrix. The design of the MNs patch was further modified 
by forming 4 channels through the corners of the patch base. This allowed enhancing 
the separation of the MNs from the base after insertion in human skin, using a small 
buffer volume. The current research represents an orientation towards enhancing the 
feasibility of designing different customized MNs and modifying their properties 
according to request. We envisage this work would provide more flexibility for 
researchers to develop and screen new designs and biomaterials for MNs 
manufacturing. Our final aim is to increase the effectiveness of drug delivery by MNs 
and ultimately enhance the patients’ compliance.  
 
4.3. Materials and Methods 
4.3.1. Materials 
HTM 140M acrylate-based 3D printing material (EnvisionTEC GmbH, Gladbeck, 
Germany) was used for 3D printing. SYLGARD 184 polydimethylsiloxane (PDMS) 
silicone elastomer (Dow Corning, Midland, US) was used as a molding material. 
Hydrogen tetrachloroaurate (III) trihydrate (HAuCl4.3H2O), gelatin type B (from bovine 
skin, gel strength ~75 g Bloom), silver nitrate, N-(3-dimethylaminopropyl)-N′-








ethylcarbodiimide hydrochloride (EDC), N-Hydroxysuccinimide (NHS), poly(vinyl 
alcohol) (Mw 31,000), sucrose, agarose, methanol, Parafilm© ‘M’ were all purchased 
from Sigma Aldrich, Steinheim, Germany. All chemicals were utilized without further 
purification. Milli-Q ultrapure water has been used for all experiments. 
 
4.3.2. Design and fabrication of microneedles molds 
The general microneedles fabrication scheme followed a three-step indirect tooling 
approach using a positive MNs mold master to create a negative mold, which ultimately 
served to replicate the final MNs patch. 
 
4.3.2.1. Design of positive microneedles mold master 
Two different MNs mold masters were designed using OpenSCAD open-source 
computer-aided design software. The MNs were designed as polyhedrons consisting 
of 10 faces each and patterned in an alternating linear array in a 10 x 10 mm sized 
area.  
 
4.3.2.2. 3D printing of positive microneedles mold master 
The design of the MNs mold master was exported as STL file and 3D printed using a 
Perfactory Micro Plus High-Res Digital Light Processing (DLP) 3D printer 
(EnvisionTEC GmbH, Gladbeck, Germany) with a horizontal resolution of 30 µm (pixel 
size) and a layer height of 15 µm. The finished mold master print was removed from 
the printing platform using a spatula, subsequently immersed in 2-propanol and placed 
in an ultrasound bath. After 5 min of sonication, the mold master was retrieved and left 
to dry. Finally, the mold master was placed in a UV-oven (EnvisionTEC GmbH, 
Gladbeck, Germany) for 10 min of post-curing treatment. 
Scanning electron microscopy was performed using a TM3030Plus tabletop scanning 
electron microscope (Hitachi High Technologies Europe GmbH, Krefeld, Germany) 
and a Zeiss Supra 40 VP scanning electron microscope (Carl Zeiss Microscopy GmbH, 
Jena, Germany). A 208HR high resolution sputter coater (Cressington Scientific 
Instruments, Watford, UK) equipped with a gold target was used to coat the specimens 
with a thin layer of gold (≈ 20 nm) prior to observation. 
 








4.3.2.3. Molding of negative microneedles mold 
A frame for the mold master was designed in Corel Draw X7 (Corel Corporation, 
Canada) and laser-cut from 5 mm acrylic using a Mini 18 CO2 laser cutter (Epilog 
Corporation, US). The frame was then secured to the mold master with several screws. 
The mold master was filled with PDMS, placed into a vacuum chamber for 30 min and 
then placed in an oven at 80 °C for 60 min. Finally, the frame was detached from the 
mold master and the negative PDMS mold was extracted. 
 
4.3.3. Preparation of nanoclusters loaded gelatin nanoparticles (NCs-GNPs) 
Gold/silver alloy nanoclusters have been synthesized as described earlier (12) by 
adding HAuCl4 to gelatin (40 mg/ml) and glutathione (0.7 mM) solution followed by 
adjusting the pH to 11 using 1N sodium hydroxide. The reaction has been carried out 
under vigorous mixing using a thermomixer (MHR, Hettich Benelux, Geldermalsen, 
The Netherlands) at 60 °C. After 6 h, a solution of silver nitrate was added in a molar 
ratio Ag/Au of 0.4, and the reaction was left to continue up to 24 h. For stopping the 
reaction, the pH of the mixture was adjusted to pH 7 using 1N HCl. 
The NPs were prepared by a two-step desolvation method (12) using methanol as 
antisolvent and crosslinking using a mixture of EDC/NHS for 18 h. They were purified 
by centrifugation (Thermo Fisher Scientific, Osterode am Harz, Germany) at 20,000 g 
for 1 h at 20 °C, followed by 3 washing steps. Then, they were characterized for size 
and zeta potential using a Zetasizer (Nano ZS, Malvern Instruments Ltd, Malvern, UK), 
as well as morphology using a transmission electron microscope (TEM) (JEOL JEM 
2100, JEOL GmbH, Freising, Germany) operating at a maximum accelerating voltage 
of 250 kV. 
 
4.3.4. Molding of nanoparticles loaded-microneedles patches 
The NPs dispersion was mixed well with a mixture of PVA/sucrose, resulting in a final 
NPs’ concentration of 1.5 mg/mL in 40% w/v PVA and 40% w/v sucrose. The mixture 
was degassed and equilibrated for 24 h to eliminate any trapped air. Each MNs mold 
was filled with 40 µL of the mixture and centrifuged (Universal 32R, Hettich, 
Geldermalsen, The Netherlands) at 3640 g for 7 min at 23 ºC. Then the extra solution 
was carefully removed from the mold and the process was repeated 3 times. The 








molds were kept under vacuum for 15 min and then 200 µL of plain PVA/sucrose 
solution was added to form the patch base. The filled molds were kept in a desiccator 
for 2 days and then the MNs were removed from the molds to be further kept and dried 
for 5 more days in the desiccator at room temperature. 
 
4.3.5.  Characterization of NCs-GNPs-loaded MNs 
4.3.5.1. Fracture force 
The MNs fracture force was determined using a TA.XT plus texture analyzer instrument 
equipped with a 10 kg load cell (Stable Micro Systems Ltd, Godalming, UK). 
Microneedles patches were secured onto the probe holder with double-sided adhesive 
tape and lowered upside-down onto a solid plate of aluminum with a test speed of 0.01 
mm/s until reaching a force of 40 N. The measured fracture force was recorded 
throughout the experiment. 
 
4.3.5.2. Penetration force  
Measurement of the force required to penetrate an artificial skin substitute with MNs 
was conducted with a TA.XT plus texture analyzer (Stable Micro Systems Ltd, 
Godalming, UK), similarly to how it is described for the fracture force determination. A 
disc of agarose gel (2% casted gel) of 6 mm thickness covered by a parafilm layer of 
127 µm thickness has been used as skin substitute [26, 27]. In this case, a skin 
substitute, which was refrigerated to maintain the gel consistency, was placed below 
the probe holder and the MNs patch was lowered into it at a test speed of 0.01 mm/s.  
 
4.3.5.3. Confocal laser scanning microscopy (CLSM) 
Spectral imaging of the MNs was performed by recording the emission spectrum (569-
724 nm) using an excitation laser of 405 nm wavelength using CLSM (LSM 710, Zeiss, 
Jena, Germany). Linear unmixing was applied to the crude signals using the previously 
recorded individual spectra of MNs components as references; NCs-GNPs and PVA. 
For 3D imaging of the MNs patch, z-stacks were recorded at 5 µm steps. In addition, 
the release of the NPs from the MNs was monitored. 50 µL PBS (pH 7.4) was added 
to MNs that were separated from the base patch on a microscopic cover slip and after 
30 s their spectral images were recorded to further be analyzed by linear unmixing. 








4.3.6. Microneedles patch modification and skin penetration studies 
To enhance the separation of MNs from the patch base after being inserted into skin 
the patches have been modified by forming a channel through each of the 4 corners 
of the squared patch. Skin penetration studies were conducted on human skin in 
comparison to the unmodified MNs patches. Excised human skin was obtained from 
abdominal plastic surgeries after the approval of the Research Ethic Committee of 
Saarland, Germany (Ärztekammer des Saarlandes, Dec. 2008) and permission of the 
volunteers. The subcutaneous fatty tissue was removed, and the skin surface was 
cleaned with water. The skin samples were stored at -20 °C to be used within less than 
6 months (13). Skin punches of 25 mm diameter were punched out, thawed and the 
surfaces were cleaned with ultrapure water. For the unmodified patches, the skin 
punches were aligned in Franz diffusion cells filled with 12 mL PBS with the stratum 
corneum facing upside. The skin was left to hydrate for 1 h, removed from the Franz 
cells, fixed over a cork plane and the MNs were pressed against the skin surface by 
thumb for 30 s and then a weight of 10 g was applied over the MNs patch. Then skin 
samples were returned carefully to the Franz cells. The setup was kept at 37 ºC while 
stirring the buffer in the receiver compartment for 3 h and then the MNs patch was 
removed (14). The modified MNs patches (with channels) were inserted into the skin 
fixed over a cork plane by thumb for 30 s. 15 µL PBS was dropped in each channel 
and then the MNs were lifted from the skin after 1 min. All the MNs patches were 
imaged by a digital camera before and after insertion into skin. The skin samples were 
mounted over a wet filter paper in a circular chamber fixed on a microscopic slide with 
the skin surface facing upwards that was covered by a cover slip (15) to be examined 
by CLSM after 30 min. Different skin areas were scanned for their spectral images that 
were further analyzed by linear unmixing using skin, PVA and NCs-GNPs recorded 
spectra as references. 
 
4.4. Results and Discussion 
4.4.1.  Design and development of MNs molds 
According to literature, different dissolving MNs common designs have been 
introduced: conical (16), pyramidal (10, 17, 18) and circular (19) or square obelisk (20). 
Researchers have manipulated the aspect ratio, angles and tip dimension to enhance 








the mechanical properties and the penetration ability of the MNs (21). Herein, we are 
introducing new designs that are inspired by a ‘Tanto blade’. Tanto is a traditional 
Japanese Samurai sword with a special design. It has 2 bevels; a short more vertical 
one (at the front) and a long straight one (extends to the hilt) (Figure 1), where the 
beveled tip allows for enhanced penetration. Figure 2A shows 2 designs for the MNs 
with the same aspect ratio; height (Z) of 800 µm and triangle base of X= 300 µm and 
Y= 200 µm. However, they differ in the ratio of the height of the 2 bevels that affects 





Figure 1. A scheme representing the steps of manufacturing tanto blade-inspired 
microneedles (MNs) loaded with NIR-emitting gold/silver nanoclusters-labelled gelatin 
nanoparticles (NCs-GNPs). This includes 1) 3D-design of 2 potential MNs using OpenSCAD 
software, 2) 3D printing of the positive mold master using DLP technology followed by UV-
curing of the resin, 3) production of negative mold replica by PDMS casting, 4) MNs preparation 
using NCs-GNPs embedded in PVA/sucrose matrix by molding, centrifugation and vacuuming, 
followed by plain base casting using PVA/sucrose only, and finally 5) drying of the MNs in a 
desiccator and removal from the mold. 
 
 
Positive master molds have been produced by digital light processing (DLP) 3D printing 
technology. The 3D printing offers flexibility in the MNs design that makes it easier for 
researchers to design and manufacture a wide range of customized MNs in the lab. 
However, it is worth mentioning that the technique has resolution limits which was as 
follows in our case: 30 µm horizontally with a layer height of 15 µm. The 3D-printed 








MNs were imaged by SEM from different perspectives as shown in Figure 2B, C and 
D. The height of the MNs was 759 and 660 µm, tip diameter was 23 and 9 µm and tip 
angle 66 and 39º for design 1 (MN1) and design 2 (MN2), respectively. All were 
measured by image J software. The masters were included in a housing (Figure 2E) 
to be further used for negative mold casting using PDMS as indicated in Figure 1. 
 
 
4.4.2. Manufacturing of MNs by molding and NPs loading 
Loading of the MNs with NPs can provide a good opportunity for controlling the delivery 
rate of drugs or biomacromolecules into skin instead of bolus dosing (5). Gelatin NPs 
are potential candidates for the delivery of macromolecules as antigens due to their 
hydrophilicity and biocompatibility (22). Rendering gelatin NPs fluorescent, by labelling 
with noble metal NCs, to act as a bioimaging probe, adds more functionality and allows 
simultaneous imaging of the NPs within MNs and skin. In our previous research we 
have introduced NIR emitting gold/silver alloy NCs-labelled gelatin as a new 
bioimaging probe that can be imaged distinctly and simultaneously with skin 
autofluorescence to provide a detailed imaging without skin pre-treatment (12). 
Gold/silver nanoclusters are composed from several to tens of atoms of the metals 
forming small structures < 2 nm. At this very small size, they show unique properties 
such as emitting fluorescence when exposed to light of a certain wavelength (23, 24). 
NIR-emitting gold and silver alloy NCs have been synthesized by using gelatin as a 
reducing agent for Au3+ and Ag+ ions and a capping agent for the formed clusters in 
the presence of glutathione (GSH) as a co-reducing agent (12). According to our 
previous research, they showed maximum emission at 700 nm when excited at 405 
nm (12). The fluorescently labelled gelatin was successfully turned into NPs with an 
average diameter of 218 nm and imaged by TEM to show the NCs’ distribution inside 
the particles (Figure 3A).  
 










Figure 2. Manufacturing of positive mold masters of 2 potential tanto blade-inspired MNs 
designs: design 1 (A) and design 2 (B). 1) Photograph of the 3D-printed MNs positive mold 
master in the final housing to be further used for PDMS casting of the negative mold and 
illustration of the 3D design of the MNs. 2-6) SEM micrographs of the 3D printed MNs showing 
top (2), back (3), front (4) and sides (5, 6). All scale bars correspond to 100 µm. 
 
 
The MNs were successfully prepared by molding PVA/sucrose (1:1) solution with the 
dispersed NPs of 1.5 mg/mL final concentration. The formed MNs showed a replicated 
morphology of the positive master with heights of 732 and 643 µm, tip diameters of 33 
and 12 µm and tip angles of 63 and 33 º for MN1 and MN2, respectively (Figure 3B 
and C). 










Figure 3. A) TEM micrograph of NCs-labelled GNPs showing the inner distribution of NCs. B) 
SEM micrograph of NCs-GNPs loaded PVA/sucrose dried MNs; design 1 (MN1) in the upper 
panel and design 2 (MN2) in the lower panel showing from left to right (front, back and both 
sides); C) magnified SEM micrographs of microneedles: MN1 in the upper panel and MN2 in 
the lower panel showing front and top view, at left and right, respectively. 
 
 
4.4.3.  Mechanical properties of MNs 
Appropriate mechanical properties are crucial for MNs application. The MNs should be 
durable to withstand the applied insertion pressure. Although, the insertion is more 
reproducible by an applicator, the manual insertion by thumb is more simple and 
convenient for patients (25). Despite the variation in the insertion force between 
individuals, Larrañeta et al. have found that the average insertion force by thumb from 
20 individuals for 30 s is 20 N (25). Herein, the insertion test has been conducted using 
a skin substitute designed to mimic the skin elasticity and the supportive tissue 
underneath using parafilm as top layer (25, 26) and a supportive agarose gel disc for 
the underlying tissue (27) (Figure 4A). The insertion forces for MN2 and MN1 were 








10.6 N and 12.9 N, respectively (Figure 4B). The retrieved patches showed robust MNs 
for MN2, while MN1 showed some of the MNs broken at the base (Figure 4C). This 
indicates higher insertion capabilities that can be attributed to the sharper tip and the 
higher ratio of the front bevel to the MNs base of MN2 compared to MN1. On the other 
hand, the fracture force of the MNs should be higher than the insertion force to avoid 
premature breakage of the MNs. Both MNs showed breaking or compression of the tip 
(Figure 5C) when forced against a solid surface (Figure 5A), while the force of fracture 
was higher for MN2 (21.9 N) than MN1 (14.1 N) (Figure 5B). Explicitly, MN2 showed 
the optimum mechanical properties for application where the force of fracture (21.9 N) 




























Figure 4. Insertion test of the MNs; design 1 (MN1) and design 2 (MN2) using skin substitute 
consisting of a 6 mm-thick agarose gel disc covered by a 127 µm-thick parafilm layer. A) 
Experimental setup using skin substitute and texture analyzer to test the insertion capability of 
MNs. B) A graph showing the minimum force (N) required for penetration of the parafilm layer 
and entering the agarose gel (mean ± SD, n=3). C) SEM micrographs of MNs retrieved after 
insertion in skin substitute. 











Figure 5. Fracture test of the MNs against metal surface using texture analyzer. A) 
Experimental setup, B) Graph showing the minimum force (N) required to fracture the MNs 
and C) SEM micrographs of MNs retrieved after fracture test showing dented tips of the MNs. 
(mean ± SD, n=5, n=4) 
 
 
4.4.4.  Spectral imaging  
Spectral analysis is a method of fluorescence imaging where the spectral information 
from the sample is recorded. This allows to separate overlapping signals into single 
chromophores by linear unmixing using an algorithm and the previously recorded 
individual reference spectra (28). We were interested in imaging NCs-GNPs, MNs 
matrix and skin separately as well as simultaneously to finally obtain detailed images 
showing the distribution of these biomaterials within the tissue. Additionally, in vitro 
examination for the NPs distribution and release from MNs were of interest. NCs-GNPs 
showed emission in the red part of the spectrum with maximum emission at 700 nm. 
On the other hand, PVA has shown a broad spectrum fluorescence when excited at 
405 nm (Figure 6A1) that was already described in literature (29). However, the 
emission spectrum of PVA has shown high similarity to skin autofluorescence 
described in our previous investigation (12).  








By recording the spectrum from the NPs-loaded MNs, one can define the distribution 
of the NPs within the MNs matrix (Figure 6A2). The figure shows the color of the 
fluorescence determined from the real spectrum; the pink and the yellow pixels are 
linked to the NPs and PVA matrix, respectively. Combining z-stacks (with 5 µm steps) 
and spectral analysis with linear unmixing, a 3D image of the MNs has been 
constructed showing the nanoparticles distributed within the MNs pillars, while the 
patch base is almost free of NPs, except from small agglomerates (Figure 6B). During 
the MNs patch manufacturing, the patch base was carefully assembled out of plain 
PVA/sucrose, in order to avoid wasting the NPs dosage. Additionally, spectral imaging 
has been used to monitor NPs release from the MNs. They were released fast from 
MNs (within 30 s) when exposed to PBS due to the fast dissolution of the MNs matrix 
as showed in Figure 6C. 
Figure 6. Characterization of MNs by confocal microscopy using 405 nm laser excitation. A1) 
Emission spectra (575 – 800 nm) recorded by CLSM for both NCs-GNPs and PVA. A2) 
Spectral images of a single microneedle (left) and top view of the MNs patch (right) colors 
displayed correspond to the weighed spectral information from the emission wavelength (Pink: 
NPs and yellow: PVA). B) Reconstructed 3D CLSM image showing NCs-GNPs signal (left) 
and co-localized NCs-GNPs and PVA signal (right). The signals were separated by linear 
unmixing using the individual emission spectra of the compounds. The colors in (B) are 
assigned arbitrarily (not based on wavelength data): red for NCs-GNPs and yellow for PVA. C) 
CLSM image of NCs-GNPs release from a single microneedle after 30 s in PBS (pH 7.4). NCs-
GNPs (red), PVA (yellow) and co-localized signal (orange). 
 








4.4.5. MNs modification and skin penetration studies 
The material selection of MNs is crucial for the development of dissolving MNs. PVA 
is one of the commonly used polymers for the fabrication of dissolving MNs (30-36). 
To enhance the solubilization of PVA MNs, blending with other polymers such as 
polyvinylpyrrolidone (PVP) (32) or sugars as sucrose (31, 36) or trehalose (33) has 
been introduced. Although, the in vitro dissolution of the MNs in PBS was very fast in 
order to release the NPs, this was not the case when the MNs were inserted into human 
skin. The MNs were still intact (Figure 7A) when removed from hydrated skin 3 h after 
insertion and the skin showed hollow pores with no sign of NPs release and penetration 
(Figure 7A). This agrees with Lee et al who reported that PVP/PVA MNs showed partial 
dissolution and weakening of the mechanical properties, while keeping structure and 
shape after insertion in skin. They encapsulated a dye that was deposited in skin after 
insertion (32). However, in our case this partial dissolution was not sufficient to induce 
the release of the NPs. This raises the question if the interstitial fluid in the skin is 
enough to induce fast dissolution of the MNs and subsequent release of the NPs. 
Leaving the NP-loaded MNs inside the skin for longer times as biocompatible implants 
will allow for matrix dissolution and NPs release inside the tissue. 
 
Consequently, we introduced an external source of fluid to induce fast dissolution and 
separation of the MNs from the patch base. This offers the advantages of a short 
insertion time for increased patient compliance, alongside with prolonging the 
residence time of MNs in the skin, so dissolution and release of the NPs will be 
facilitated. In this regard, we have modified the MNs patch by forming 4 channels in 
the corners of the square patch. These holes allowed the introduction of small volumes 
of PBS, post-MNs skin insertion, which diffused due to the capillary forces and resulted 
in fast separation of MNs from the base into the skin (Figure 7B). Both MN1 and MN2 
were examined for skin penetration and deposition of NPs into human skin (Figure 7C). 
The retrieved MNs patch, after 1 min of skin insertion, showed efficient separation of 
the MNs from the base as shown in Figure 7C. The deposited MNs inside the skin were 
imaged by CLSM using spectral analysis. Linear unmixing was effective for separating 
the signal of the NPs from that of skin and PVA. However, the separation of both skin 
and PVA signal was not possible due to the high similarity in their fluorescence  











Figure 7. A) Digital images unmodified MN2 patch after 3 h of insertion into skin (left) and 
reconstructed 3D CLSM image of skin (right) after the removal of the MNs showing empty 
holes. Skin has been imaged by recording the autofluorescence of skin upon excitation with a 
405 nm laser. B) A scheme shows the modification of the MNs patch by forming channels at 
the 4 corners, then application to human skin punch followed by adding PBS through the 
channels to induce fast solubilization of the MNs and detachment from the patch base. C) The 
effect of MNs morphology and modifying the MNs patches on skin penetration of MN1 and 
MN2, showing the separation of the MNs from the base (left panels) after insertion for 1 min in 
skin. The inserted MNs have been imaged in skin by CLSM (right panels) where the signal of 
NCs-GNPs (red), inside the MNs, have been separated from skin and PVA signals (green) by 
linear unmixing upon excitation at 405 nm. The signal of PVA cannot be separated from that 








of skin, due to their similar fingerprint. The MNs can be distinguished from skin by their obvious 
morphology (referred to by yellow arrows). MN1 and MN2 penetrated the skin to about 300 
and 550 µm from the skin surface, respectively.  
 
 
fingerprint (12). The obtained information allowed us to detect the NPs penetration 
depth by linear unmixing. Additionally, the depth of the MNs insertion inside the skin 
could be identified as a result of the well-defined shape of the MNs, which reached 300 
and 550 µm for MN1 and MN2, respectively (Figure 7C). The findings support the 
superior penetration capability of MN2 as tested earlier using texture analyzer. Finally, 
MNs patch modification with the corner channels proved to be a simple and convenient 
method to enhance the dissolution and separation of PVA-based MNs from the patch 
base. This modification can further open the door to test and approve the suitability of 
variable materials for dissolving MNs fabrication for NPs delivery with minimized 
administration time to enhance the patient compliance. Additionally, spectral analysis 
is an attractive method that offers more detailed imaging for MNs in skin depending 
only on skin autofluorescence with no need for skin pre-treatment. 
 
4.5. Conclusion 
As research is highly demanding the development of dissolving MNs to improve their 
performance for painless transdermal delivery of drug payloads, we, herein, introduce 
a complete guide for customization of MNs in the lab. Feasible and cost-effective 
customization of the design to increase skin penetration of MNs was successfully 
achieved by 3D-printing of master molds using a desktop DLP 3D printer. Deviating 
from the typical geometries of MNs, pyramidal or conical, researchers are enabled to 
produce various geometries and test their effectiveness as robust and sharp MNs. The 
tanto blade-inspired designs proved to be effective for skin penetration without pre-
mature fracture as the fracture force was higher than the insertion force. Modifying the 
aspect ratio of the penetrating front and the tip’s dimension and angle rendered the 
MNs sharper and improved their skin penetration. Further, MNs patches were 
engineered to speed up the dissolution and separation of MNs from the base into skin. 
This was achieved by carving 4 channels at the corners of the patch to introduce small 
amounts of a buffer solution post-skin insertion of the MNs. This fostered fast 








detachment of the MNs from the base plate. The connected shorter administration time 
should ultimately lead to an increased patient compliance. Additionally, loading of the 
MNs with NIR-emitting NCs-GNPs proved to be an effective imaging probe to visualize 
NPs distribution within the MNs, their release in vitro and their skin penetration. 
Spectral imaging with linear unmixing could be demonstrated as a new promising tool 
for simultaneous imaging of the delivery system and skin tissue. Finally, we have 
introduced new techniques to improve the performance of dissolving MNs and their 
imaging to serve as a platform to facilitate design customization of MNs by researchers 
in the lab. 
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5. Functionalized Theranostic Nanovaccine for Targeting Dendritic 
Cells and Modulation of Immune Response 
 
5.1. Abstract 
Nanoparticle-based delivery systems have gained interest for enhancing the efficacy 
and modulating the processing pathways of antigens. In the current study, theranostic 
gelatin nanoparticles modified by NIR-emitting gold and silver alloy nanoclusters and 
loaded with ovalbumin (OVA) as a model antigen were developed. Two different 
designs of the nanoparticles were introduced; positively charged nanoparticles with 
OVA displayed over the surface (S-NPs) and in the other, OVA is encapsulated in the 
nanoparticles’ matrix and the surface was functionalized by dextran for dendritic cells 
targeting (Dex-NPs). The nanoparticles showed a particle size of 210 and 305 nm and 
zeta potential of +25.6 and -23.9 mV, for S-NPs and Dex-NPs, respectively.. Both 
nanoparticles (Dex-NPs and S-NPs) succeeded to induce maturation of murine bone 
marrow-derived dendritic cells (BMDCs) evaluated by CD86, CD80, CD40 markers 
and MHC II. While, Dex-NPs showed no cytotoxicity to BMDC, S-NPs was cytotoxic at 
a concentration equivalent to 40 µg/ml loaded OVA. The interaction of nanoparticles 
with BMDCs was quantitatively evaluated by flow cytometry and the nanoparticles 
internalization by the cells were imaged by confocal laser scanning microscopy. 
Interestingly, Dex-NPs, rather than S-NPs, modulated the presentation pathway of 
OVA by dendritic cells to be presented by both MHC II and MHC I to enhance the 
proliferation of CD4+ and CD8+, respectively. This highlights the potential of the 
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Vaccines have been an effective tool for protection against diseases by activating and 
building the memory of the immune cells to fight against microbes and allergens. On 
the other hand, diseases caused by intracellular pathogens (e.g. viruses) and cancer 
which is caused by endogenous proteins require more focus for development of 
effective vaccines (1). Antigen-presenting cells (APCs), especially dendritic cells 
(DCs), can present exogenous and endogenous antigens on major histocompatibility 
complex (MHC) class II and class I proteins to interact with helper T-cells (TH, CD4+) 
and cytotoxic T-cells (CTL, CD8+), respectively. In turn, CD4+ cells activate B-cells to 
produce antibodies against the antigen, while CD8+ cells attack and destroy the virus-
infected or cancer cells (2). Despite being challenging, the development of tumor 
vaccines using exogenous antigens would be achieved by enhanced uptake of the 
antigen or cross-presentation, involving escape from lysosomal degradation. So, the 
antigens are degraded by cytosolic proteasomes as endogenous antigens to be 
presented on MHC class I molecules (3).  
 
Nowadays, nanoparticles provide an attractive strategy for enhancing antigen delivery. 
They offer several advantages that overcome the demerits of soluble antigens 
application (4); 1) antigen encapsulation provides the protection of the antigen against 
premature undesired degradation, 2) antigen displaying over the nanoparticles’ surface 
mimic the natural way of antigen presentation by the pathogen, 3) controlling and 
prolonging the release of the antigen to intensify the exposure of the immune system, 
4) concomitant loading of the antigen and immune adjuvant is possible to enhance the 
limited immunogenic effect of most proteins (2, 5). Nanoparticles can contribute to 
modulating the immune response of antigens by modifying their properties such as 
size and surface properties. For instance, decorating the nanoparticles surface with 
targeting moieties for active targeting of APCs is an attractive approach for enhancing 
antigen receptor-mediated uptake (2). On the other hand, surface modification with 
poly ethylene imine (PEI), which act as a proton-sponge, can enhance the lysosomal 
escape of the antigen to the cytosol (6). Both strategies can help to induce antigen 
presentation to MHC class I and thus the activation of CTL.  








Different nanocarriers have been introduced for loading and antigen delivery, among 
which polymeric nanoparticles have gained interest. Different categories of polymers 
have been tested including poly (esters), poly (α-hydroxy acids) (5, 7, 8), proteins (9, 
10) and polysaccharides (4, 11, 12). Gelatin is a hydrophilic biodegradable polypeptide 
polymer which provides a good opportunity for encapsulating high payload of antigens 
under non-harsh conditions (13). This is important to preserve the proteins’ 
conformation which, in turn, is important for their immunogenic activity. Additionally, 
gelatin is of low immunogenicity (14) which is an important characteristic for an optimal 
vaccine nanocarrier. Gelatin nanoparticles (GNPs) have been investigated for the 
delivery of antigens (models) such as tetanus toxoid (15) and ovalbumin (10, 16).  
 
In the current work, we present a theranostic functionalized gelatin nanoparticles for 
modulating the immune response of OVA as a model antigen. The NIR-emitting gold 
silver nanoclusters-labelled gelatin nanoparticles were designed as a novel imaging 
probe. Two designs for OVA loading have been adapted, direct loading and cross 
linking and the other is surface loading by electrostatic interaction to poly-l-lysine 
coated GNPs. OVA-encapsulated nanoparticles were further decorated with dextran, 
which is known for its affinity to a group of receptors on DCs; the DC-SIGN (dendritic 
cell-specific intercellular adhesion molecule 3-grabbing nonintegrin) family receptors: 
DC-SIGN (CD209) and L-SIGN (the liver and lymphatic endothelium homologue of DC-
SIGN), the mannose receptor (CD206), and langerin (17). The functionalization of the 
nanoparticles by dextran was tested for its capability to enhance the enhance NP 
uptake and thus the antigen uptake, bone marrow-derived dendritic cells (BMDCs) 
activation and induction of both CD4+ and CD8+ proliferation. 
 
5.3. Materials and Methods 
5.3.1. Materials 
Hydrogen tetrachloroaurate (III) trihydrate (HAuCl4.3H2O), gelatin type B (from bovine 
skin, gel strength ~75 g Bloom), silver nitrate, albumin from chicken egg white, poly-L-
lysine hydrobromide (Mw 30,000-70,000), N-(3-dimethylaminopropyl)-N′-
ethylcarbodiimide hydrochloride (EDC), N-Hydroxysuccinimide (NHS), dextran 








sulphate sodium salt (from Leuconostoc species, Mw 100,000), D-(+)- trehalose 
dihydrate, methanol were all purchased from Sigma Aldrich, Steinheim, Germany. 
Ovalbumin EndoFitTM (VacciGradeTM) was purchased from InvivoGen, Toulouse, 
France. Fetal bovine serum (FBS), Hank's Balanced Salt Solution (HBSS),4′,6-
diamidino-2-phenylindole (DAPI) and Alexa Fluor® 488 conjugate of Concanavalin A 
were purchased from ThermoFisher scientific, Paisley, United Kingdom. Fixable 
viability dye eFluor780 was purchased from eBioscience, Thermo Fisher, Paisley, 
United Kingdom. Antibodies: (CD4-eFluor450 (clone RM4-5), CD8-eFluor506 (clone 
53-6.7), CD11c-eFluor450 (clone N418) and CD62L-APC-eFluor780 (clone MEL-14) 
were purchased from eBioscience, Thermo Fisher, Paisley, United Kingdom. CD11b-
PerCp/Cy5.5 (clone M1/70), CD40-APC (clone 3/23), CD86-BV605 (clone GL-1) and 
MHC-II-Alexa700 (clone M5/114.15.2) were purchased from Biolegend, San Diego, 
CA, USA.  CD80-PE (clone 16-10A1) was purchased ImmunoTools, Friesoythe; 
Germany). All other chemical used for cell studies, cell culture media, Dulbecco’s 
phosphate-buffered saline (DPBS), 4-(2-hydroxyethyl)-1-piperazineethanesulfonic 
acid) buffer (HEPES), L-glutamine, penicillin and streptomycin were purchased from 
Sigma Aldrich, Steinheim, Germany, unless otherwise stated.  
 
5.3.2. Preparation of fluorescent ovalbumin loaded-gelatin nanoparticles 
5.3.2.1. Preparation of gold-silver nanoclusters-labelled gelatin 
Gold and silver alloy nanoclusters have been synthesized as described earlier (18) by 
adding HAuCl4 to gelatin (40 mg/ml) and glutathione (0.7 mM) solution followed by 
adjusting the pH to 11 using 1N sodium hydroxide. The reaction has been carried out 
under vigorous mixing at 1000 rpm in a thermomixer (MHR, Hettich Benelux, 
Geldermalsen, The Netherlands) at 60 °C. 6h after the start of the reaction, a solution 
of silver nitrate was added in a molar ratio Ag/Au of 0.4, and the reaction continued to 
24h. For stopping the reaction, the pH of the mixture was adjusted to 7 using 1N HCl. 
 
5.3.2.2. Preparation of gelatin nanoparticles 
The nanoparticles were prepared by two step desolvation method using methanol as 
antisolvent and crosslinking using a mixture of EDC/NHS for 18h (18). They were 








purified by centrifugation (Thermo Fisher Scientific, Osterode am Harz, Germany) at 
20,000 g for 1h at 20 °C followed by washing that was repeated 3 times.  
 
5.3.2.3. Ovalbumin surface loading 
The pH of gelatin nanoparticles dispersion has been adjusted to 7.4, followed by 
addition of PLL (1mg/ml) solution and stirring for 1h (weight ratio NP: PLL, 25:1). The 
nanoparticles have been purified by centrifugation (20,000 g, 30 min, 20 °C) and 
washing twice with MilliQ® water (MerckMillipore, Darmstadt, Germany). Further 
interaction with ovalbumin (50 µg/mg of NPs) has been conducted for 1h, followed by 
purification. 
 
5.3.2.4. Ovalbumin encapsulation and surface functionalization 
Direct loading of OVA has been achieved by addition of OVA to gelatin solution after 
the first precipitation (50 µg OVA / mg of gelatin). The mixture has been cross-linked 
with EDC/NHS for 18h. The purified nanoparticles have been functionalized by layer-
by-layer coating with PLL followed by dextran sulphate (weight ratio of NP : PLL: 
Dextran, 50: 2: 1.5). For storage and further use, all types of nanoparticles; plain (P-
NPs), OVA-surface loaded (S-NPs) and OVA-encapsulated dextran-functionalized 
nanoparticles (Dex-NPs), have been freeze dried with trehalose with weight ratio of 
1:10 (NP: trehalose). 
 
5.3.3. Nanoparticles characterization 
The nanoparticles were characterized for size and Zeta potential using Zetasizer (Nano 
ZS, Malvern Instruments Ltd, Malvern, UK) and morphology using transmission 
electron microscope (JEOL JEM 2100) operating at a maximum accelerating voltage 
of 250 kV, after staining of the nanoparticles dispersion with uranyl acetate. The 
fluorescence spectra of the S-NPs and Dex-NPs has been compared to P-NPs of the 
same concentration (5 mg/ml) when excited at 405 nm. The spectra have been 
recorded from 550-850 nm using microplate reader (Infinite M200, Tecan group Ltd, 
Männedorf, Switzerland). 
 








5.3.4. Entrapment efficiency  
For both types of loaded nanoparticles (S-NPs and Dex-NPs), unloaded OVA has been 
quantified in the supernatants after centrifugation and particles purification against 
blanks. 5 ml of the nanoparticles dispersion has been centrifuged at 24,000 g for 2h to 
sediment all the nanoparticles and get clear supernatant. OVA has been analysed for 
their intrinsic fluorescence at 340 nm when excited at 295 nm using Corning ® black 
96-well flat bottom plates (Sigma Aldrich, Steinheim, Germany) and microplate reader 
(Infinite M200, Tecan group Ltd, Männedorf, Switzerland). The sedminented 
nanoparticles have been further freeze-dried and weighed. The entrapment efficiency 
(EE %) and loading capacity (LC %) have been calculated as follows: 
 
EE % = 
𝑇𝑜𝑡𝑎𝑙 𝑎𝑚𝑜𝑢𝑛𝑡 𝑜𝑓 𝑂𝑉𝐴  𝑎𝑑𝑑𝑒𝑑 𝑡𝑜 𝑡ℎ𝑒 𝑝𝑟𝑒𝑝𝑎𝑟𝑎𝑡𝑖𝑜𝑛 (µ𝑔)−𝑈𝑛𝑙𝑜𝑎𝑑𝑒𝑑 𝑂𝑉𝐴 𝑎𝑚𝑜𝑢𝑛𝑡 (µ𝑔)
𝑇𝑜𝑡𝑎𝑙 𝑎𝑚𝑜𝑢𝑛𝑡 𝑜𝑓 𝑂𝑉𝐴  𝑎𝑑𝑑𝑒𝑑 (µ𝑔)
 𝑥 100 
 
LC% = 
𝑇𝑜𝑡𝑎𝑙 𝑎𝑚𝑜𝑢𝑛𝑡 𝑜𝑓 𝑂𝑉𝐴  𝑎𝑑𝑑𝑒𝑑 𝑡𝑜 𝑡ℎ𝑒 𝑝𝑟𝑒𝑝𝑎𝑟𝑎𝑡𝑖𝑜𝑛 (µ𝑔)−𝑈𝑛𝑙𝑜𝑎𝑑𝑒𝑑 𝑂𝑉𝐴 𝑎𝑚𝑜𝑢𝑛𝑡 (µ𝑔)
𝑊𝑒𝑖𝑔ℎ𝑡 𝑜𝑓 𝑡ℎ𝑒 𝑛𝑎𝑛𝑜𝑝𝑎𝑟𝑡𝑖𝑐𝑙𝑒𝑠 (µ𝑔)
 𝑥 100 
 
5.3.5. Release studies 
Freeze-dried nanoparticles have been dispersed in 6 ml of phosphate buffer saline 
(PBS, pH 7.4) to give a final dispersion of 2 mg/ml in 15-ml falcon tubes. They were 
incubated at 37 ºC and shaken at 500 rpm using a thermomixer (MHR, Hettich 
Benelux, Geldermalsen, The Netherlands). Samples of 400 µl have been withdrawn at 
different time intervals, centrifuged at 24000 g for 30 minutes and the supernatant was 
analysed for OVA concentration by measuring the intrinsic fluorescence (λex = 295 nm 
and λem = 340 nm).  
 
5.3.6. Cellular interaction with bone marrow-derived dendritic cells (BMDCs) 
5.3.6.1. Generation of BMDCs 
Bone marrow-derived precursors were harvested from femurs/tibias of C57BL/6 mice 
and were cultured in RPMI 1640 complete medium (10% v/v FBS, 2 mM L-glutamine, 
20 ng/mL Granulocyte-macrophage colony-stimulating factor (GM-CSF), 100 U/mL 
penicillin, 0.1 mg/mL streptomycin). 2 x 106 cells were cultured in 10 mL medium in 10 








cm petri dishes (non-treated). At day 3, 10 mL of fresh medium was added and at day 
5, 50% of medium was replaced. At day 8, bone marrow-derived DCs (BMDCs) were 
harvested. 
 
5.3.6.2. Cell viability, nanoparticles uptake and cell activation 
3 x 105 (for uptake) or 1 x 105 (for activation) BMDCs were cultured overnight (16h) in 
96-well V-bottom plates (non-treated) in 150 µL of complete medium containing 
different concentrations of Endofit™ Ovalbumin, or the different gelatine nanoparticle 
preparations. The next day, cells were washed with DPBS and resuspended in 20 µL 
of an anti-CD16/32 hybridoma supernatant (blocking) and incubated on ice. After 5 
min, 20 µL of staining mix consisting of fixable viability dye eFluor 780 (1:1500) (for 
viability assessment), anti-CD11c-eFluor450 (1:50), anti-CD11b-PerCp-Cy5.5 (1:100), 
anti-CD40-APC (1:100), anti-CD80-PE (1:100), anti-CD86-BV605 (1:100), and 
antiMHC II-Alexa700 (1:100) were added. Cells were incubated on ice for 15 min, 
washed with PBS, 1% BSA, 2mM EDTA, and analysed on a Cytoflex S cytometer 
(Beckman Coulter Life Science Austria, Vienna, Austria).Gating strategies for cell 
viability Np uptake and cell activation are described in Figure S18 and S19 (Annex 
section). 
 
5.3.6.3. Confocal laser scanning microscopy (CLSM) 
BMDCs in RMPI 1640 supplemented with 10% FBS, 100 U/ml Pencillin/Streptomycin, 
50 μM β-mercaptoethanol and 20 ng/ml of GM-CSF (1.2 x106 cells, 200 µl) were 
seeded in 8-well imaging chamber and incubated at 37 ºC and 5% CO2 for 24h to attach 
to the bottom of the well. The medium with unattached cells were removed and 
replaced with NPs (P-NPs, S-NPs and Dex-NPs) equivalent to 40 µg/ml OVA. After 6h 
of incubation, the nanoparticles were removed and the cells were washed 3 times with 
HBSS buffer. The cells were fixed by incubation with ice cold methanol for 20 min. 
Then, they were washed and incubated with 3 nM DAPI for 20 min for nucleus staining, 
followed by washing and incubation with 10 µg/ml Alexa Fluor® 488 conjugate of 
Concanavalin A for 20 min for staining the cell membrane. The cells were washed 
again to remove the excess dye and stored in HBSS at 4 ºC to be further examined 








with confocal laser scanning microscopy. The cells were excited at 405 nm and 
emission was recorded from 600-740 nm, followed by signal separation of gold/silver 
nanoclusters-modified gelatin nanoparticles by linear unmixing using pre-recorded 
spectral reference to avoid any possible interference from DAPI that is excited at the 
same wavelength. Then the cells were excited at 405 and 488 nm and the emission 
was recorded at 410 – 495 nm and 495 -630 nm for detection of DAPI and of Alexa 
Fluor® 488, respectively. Finally, the recorded images were merged.  
 
5.3.7. Co-culture with naïve T cells 
Spleens from OT-I and OT-II mice were aseptically removed and transferred to 40 mm 
Petri dishes containing 500 µL DPBS and homogenized using the back of a sterile 
plunger from a 2 mL syringe. The suspensions were transferred into 1.5 mL Eppendorf 
tubes. After 3-5 min incubation at room temperature (until debris had settled), the 
monodisperse cell suspension was transferred into a 15 mL tube, pre-filled with 7 mL 
of ammonium chloride potassium   red blood cell lysis buffer (0.15M NH4Cl, 10 mM 
KHCO3, 0.1 mM Na2EDTA, pH 7.2-7.4) and incubated for 7 min at room temperature. 
Tubes were filled up with 6 mL of DPBS, centrifuged for 5 min at 260 g at room 
temperature, and the pellets were resuspended in 10 mL warm DPBS containing 1 µM 
carboxyfluorescein diacetate succinimidyl ester (CFSE). After 10 min incubation at 37 
°C, 1 mL of FBS followed by 2 washing steps with T cell medium (RPMI, 10% FBS, 25 
mM HEPES, 2 mM L-glutamine, 100 µg/mL streptomycin, 100 U/mL penicillin). Pellets 
were resuspended in 0.5 mL T cell medium containing anti-CD62L-eFluor780 (1:150) 
and anti-CD4-eFluor450 (1:200) or anti-CD8-eFluor506 (1:100) and incubated on ice 
for 30 min. After washing with DPBS, cells were resuspended in T cell medium and 
naïve CD4+ (OT-II) and CD8+ (OT-I) T cells were sorted on a flow cytometry Aria III 
cell sorter (BD Biosciences, Heidelberg, Germany) based on high expression of 
CD62L. 
15,000 sorted naïve T cells were co-cultured with 5,000 BMDCs in a 50:50 mixture of 
complete BMDCs and T cell medium in 96-well round bottom plates in the presence or 
absence of different concentrations of OVA or gelatin nanoparticles. After 4 days of co-
culture, cells were harvested, washed with DPBS and resuspended in 30 µL of staining 








mix consisting of fixable viability dye eFluor 660 (1:3000), anti-CD4-eFluor450 (1:200) 
or anti-CD8-eFluor506. Cells were incubated on ice for 10 min, washed with PBS, 1% 
BSA, 2 mM EDTA, and analysed on a Cytoflex S cytometer. Gating strategies used for 
CD4+ (OT-II) is shown in Figure S20 (Annex section) and CD8+ (OT-I) in Figure S21 
(Annex section). 
 
5.3.8. Deposition studies in skin using P.L.E.A.S.E (Precise Lasers Epidermal 
System) device 
Excised human skin was obtained from abdominal plastic surgeries after the approval 
of the Research Ethic Committee of Saarland, Germany (Ärztekammer des 
Saarlandes, Dec. 2008) and permission of the volunteers. The subcutaneous fatty 
tissue was removed and the skin surface has been cleaned by water. The skin samples 
were kept in aluminum foils and stored in -20 °C to be used within less than 6 months. 
Skin punches of 12 mm diameter have been cut and thawed and the surface was 
cleaned with water. For skin microporation, the punches have been treated with 
P.L.E.A.S.E.® (Precise Lasers Epidermal System) device (Pantec Biosolutions AG, 
Ruggell, Liechtenstein) using the following parameters: Fluence 56.8 J/cm2, 5 
pulses/pore, microporation density 10 % and array size of 10 mm. 50 µl of 2 mg/ml 
fluorescent gold/silver nanoclusters-modified gelatin nanoparticles has been added to 
the perforated skin surface. The skin punch was carefully transferred to a petri dish 
and 0.5 ml of PBS was added around the tissue, to keep it hydrated, to be incubated 
for 1h at 37 °C. After that, the skin surface has been cleaned and the skin has been 
cut longitudinally into three pieces, embedded in Tissue Tech© and instantly frozen 
using liquid nitrogen. The skin has been longitudinally sectioned by a cryotome and 
examined by CLSM. Spectral analysis and linear unmixing has been applied to 
separate NPs from skin signal as described before (18). 
 
5.4. Results and Discussion 
5.4.1. Design, preparation and characterization of ovalbumin-loaded 
nanoparticles 
In the current study we have designed nanoparticulate systems with different 








properties for the delivery of OVA as a model antigen. We have selected gelatin as 
biopolymer for the nanoparticle preparation. Gelatin is the product of collagen 
hydrolysis and is generally regarded as safe (GRAS) by the FDA. It is biodegradable 
and biocompatible with low or negligible antigenicity (19). It offers high capacity for 
delivery of biomacromolecules such as antigens (13). Due to its peptide nature, it is 
rich in functional groups that allow for cross linking and chemical modification of the 
produced nanoparticles (20). 
 
Gelatin has been modified to be fluorescent by using it as a reducing and stabilizing 
agent for the synthesis of gold-silver alloy nanoclusters (NCs). The formed 
nanoclusters are ultra-small structures of size less than 1 nm and emit light in the near 
infra-red region (λem= 700 nm) (18). The nanoclusters-modified gelatin was further 
utilized for nanoparticle preparation by two-step desolvation method. The first 
desolvation step was to precipitate the high molecular weight polymer, while getting rid 
of the low molecular weight chains that can cause irreversible aggregation of the 
nanoparticles (21). Then, the high molecular weight polymer was used to prepare 
nanoparticles of uniform particle size. They showed a particle size of 205.7 nm with a 
polydispersity index (PDI) of 0.14. The particles showed a zeta potential of -6.2 mV 
(Figure 1B and C). 
 
For loading OVA, two designs have been considered (Figure 1A): surface loading and 
encapsulation. The surface loading allows for multiple antigen display which mimics 
the natural display of the antigen by pathogens. Gelatin nanoparticles were cationized 
by electrostatic interaction with poly L-lysine (PLL) by pH adjustment to 7 where gelatin 
B is negatively charged (pI 4-5) and PLL is positively charged (pI 9). OVA was loaded 
by electrostatic interaction with the cationic surface of the nanoparticles. The 
nanoparticles showed a z-avg for particle size of 210.5 nm, a PDI of 0.102 and the zeta 
potential of the nanoparticles was +25.6 mV (Figure 1B and C). Even though the OVA 
is displayed on the surface, the surface charge was positive due to the fact that OVA 
is only a weak polyanion; not compensating the existing positive surface charge. OVA 
concentration and interaction time were optimized to 50 µg/ml and 1h respectively to  
































Figure 1. A) Design of ovalbumin (OVA) loaded gelatin nanoparticles (GNPs). The 
nanoparticles are modified with gold and silver alloy nanoclusters (NCs). S-NPs: OVA is loaded 
on the surface by electrostatic interaction with the positively charged GNPs (modified by poly-
l-lysine (PLL)) and Dex-NPs: OVA is encapsulated within the matrix of GNPs and the NPs 
surface was functionalized by dextran sulphate, B) particles size (mean ± SD, n=3) and C) zeta 
potential measurements (mean ± SD, n=3) of different NPs (plain GNPs (P-NPs), S-NPs and 
Dex-NPs), D) Transmission electron microscopy images of the nanoparticles. Scale bar is 0.2 
µm and E) Fluorescence spectra of Dex-NPs and S-NPs in comparison to P-NPs while 
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obtain nanoparticles with the highest possible loading and colloidal stability at the same 
time. Lower PLL concentrations with higher loading concentration of OVA and higher 
interaction times resulted in reduced colloidal stability that can be attributed to reduced 
surface positive charge or the high density of OVA on the surface that can cause 
possible protein-protein inter-particle interaction by hydrophobic interactions or Van 
der Waals forces.  
 
For detection of OVA EE%, the unreacted OVA was analysed by intrinsic fluorescence 
measurement of the protein. The measured fluorescence (λex = 295 nm and λem=340 
nm) is characteristic for the tryptophan residues in OVA (22, 23). This method was 
selective for OVA with no interference of gelatin (at the tested concentrations), as 
gelatin lacks tryptophan in its structure (24). Other analysis methods have been used 
for quantitation of the protein loading in gelatin nanoparticles; for example OVA loading 
in gelatin nanoparticles was evaluated semi-quantitatively by SDS-PAGE 
electrophoresis and Coomasie-Blue staining (25), and bovine serum albumin (BSA) 
loading in gelatin nanoparticles has been detected using HPLC method (26). However, 
the current developed method represents a simple and selective method for detection 
of tryptophan-containing proteins (such as OVA and BSA) in presence of gelatin. The 
analysis revealed that the EE% of OVA in S-NPs was 83.58 + 8.14%. And the LC% 
was 3.86 + 0.66%. 
 
On the other hand, encapsulation can protect the antigen from degradation. For OVA 
encapsulation in gelatin nanoparticles, OVA was added to gelatin before the second 
precipitation step. The nanoparticles were cross-linked by EDC/NHS mixture which is 
a zero-length cross-linker that conjugates the amino and carboxylic groups of the 
amino acids (27). The surface of the nanoparticles was functionalized by dextran for 
targeting DCs. Dextran is a biocompatible, linear polysaccharides of glucose with a 
prevalence of 1,6-linked units. Dextran is taken up by APCs such as DCs and 
macrophages due to interaction with specific receptors: the family of C-type lectins, 
namely mannose receptors (MRs), dendritic adhesion cell (DCs)-specific molecule-3 
intercellular (ICAM-3)-grabbing nonintegrin (DC-SIGN), the liver and lymphatic 








endothelium homologue of DC-SIGN (L-SIGN), and langerin (17). The surface 
functionalization was achieved by electrostatic interaction of dextran sulphate to PLL-
modified gelatin nanoparticles. This was proven by measuring zeta potential that was 
-23.9 mV (Figure 1C). Encapsulation of OVA in GNPs resulted in larger particle size 
(Z-avg 300.5 nm, PDI 0.194) compared to the surface loading (Figure 1B). This size of 
nanoparticles is suitable for targeting resident DCs in skin for transcutaneous 
vaccination. Nanoparticles size can manipulate the immune response, where 
nanoparticles of size 20-200 nm can drain passively to lymph nodes to be taken up by 
DCs there and larger particles are preferentially taken up by DCs at site of application 
(28). Freeze drying of both formulations in presence of trehalose (1:10 by weight NP: 
trehalose) preserved the size and zeta potential after reconstitution. The EE% of OVA 
was 72.9 + 14.9% and the LC% was 5.34 + 1.84%, which were detected indirectly by 
measuring the concentration of the unloaded OVA in supernatants after nanoparticles 
centrifugation by fluorimetic analysis.  
 
TEM imaging of the nanoparticles (Figure 1D): plain (P-NPs), surface-loaded (S-NPs), 
and OVA-encapsulated with surface functionalization by dextran (Dex-NPs) showed 
spherical morphology for all formulations. Dex-NPs showed larger nanoparticles 
compared to P-NPs and S-NPs which supports the results obtained by photon-
correlation spectroscopy. Furthermore, the images showed the presence of NCs in all 
nanoparticles. The fluorescence properties were evaluated for all formulations upon 
excitation at 405 nm by recording the fluorescence spectra. It was found, that the 
loading OVA is negligibly affecting the fluorescence of GNPs (Figure 1E). 
 
 
5.4.2. Ovalbumin release 
OVA release from both S-NPs and Dex-NPs was performed in PBS, pH 7.4 over 
specified time intervals for a period of 3 and 60 days for S-NPs and Dex-NPs, 
respectively. S-NPs showed a burst release (31 %) after 1h followed by a slower 
release over 3 days to reach 71 % at the end of the release study (Figure 2A). This 
can be attributed to the surface loading of OVA post-preparation of the nanoparticles 








and the electrostatic forces that binds OVA to NPs. On the other hand, Dex-NPs 
showed a slow release profile, with no burst effect, that reached just 8.4 % after 60 
days (Figure 2B). This proves the cross-linking of OVA and gelatin during NP 
formation. This can provide a protection for the antigen form environmental conditions 
till the uptake of the NPs by APCs. Then the NPs can be processed within the cells to 










Figure 2. OVA release from nanoparticles at phosphate buffer saline (PBS) of pH 7.4 at 37º C 
at different time intervals: A) from S-NPs and B) Dex-NPs. (mean ± SD, n=3) 
 
5.4.3. Interaction of nanoparticles with BMDCs 
Cytotoxicity of the different NPs have been evaluated using BMDCs (Figure 3A). Both 
Dex-NPs and P-NPs caused no cytotoxicity at all tested concentrations of the NPs 
equivalent to 10-40 µg/ml of OVA. Whereas, S-NPs showed cytotoxicity (a reduction 
in cell viability by 38%) when the cells exposed to NPs concentration equivalent to 40 
µg/ml of OVA. This can be attributed to the positive charge of the NPs that have been 
previously reported for their potential cytotoxic effect (29).  
 
Maturation of BMDC have been assessed by flow cytometry by detecting the 
upregulation of CD40, CD80 and CD86 maturation markers (Figure 3B, C and D)(30, 
31), and MHC class II for antigen presentation to CD4+ (Figure 3E) (31, 32). Dex-NPs  
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Figure 3. A) Cytotoxicity of the nanoparticles at different concentrations compared to OVA and 
lipopolysaccharides (LPS) represented as the % of viable bone marrow dendritic cells 
(BMDCs). Maturation and activation of BMDCs evaluated by measuring B) CD40, C) CD80, 







































Figure 4. A) uptake/interaction of NPs with BMDCs analyzed by flow cytometry (mean ± SD, 
n=3) and B) confocal laser scanning microscopy images of NPs internalization by BMDCs, 
blue: DAPI staining the nucleus (ex at 405 nm, em 410 – 495 nm), green: Concanavalin A - 
Alexa Flour 488 staining the cell membrane and cytoplasm (ex at 488 nm, em 495 - 630 nm) 
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showed superiority in the ability to induce DCs maturation compared to S-NPs and P-
NPs, where P-NPs showed the lowest influence.All formulations showed 
concentration-dependent response in term of DCs maturation, and at the same time a 
more pronounced effect than the soluble antigen. 
 
Cellular interaction/uptake with NPs was examined quantitatively using flow cytometry 
(Figure 4A), which provides information about the total number of cells interacting with 
NPs by measuring the fluorescence of NCs. Dex-NPs showed superiority in uptake by 
BMDCs over S-NPs and P-NPs for all the tested concentration NPs concentrations  
equivalent to 10-40 µg/ml OVA. Higher % uptake of Dex-NPs of 43.5% was noticed 
(compared to S-NPs (10.8 %) and P-NPs (11%) when the cells were treated with NPs 
concentration equivalent to 10 µg/ml OVA. This indicates the significance of 
nanoparticles decoration with dextran, as a potential polyscharride that can target 
receptors expressed on dendritic cells such as mannose receptors, for enhancing the 
uptake of the nanoparticles.  
 
BDMCs incubated with NPs equivalent to 40 µg/ml OVA were visualized by CLSM to 
detect the uptake and localization of NPs (Figure 4B), which cannot be predicted from 
the flow cytometry measurements. It has been found that Dex-NPs are internalized 
within the cells proofing the uptake of NPs. S-NPs showed in some cells concentration 
of the NPs on the cellular membrane due to the electrostatic interaction between the 
positively charged NPs and the negatively charged cell membrane. For P-NPs, some 
NP agglomeration have been shown to be outside the cells, beingconnected to a lower 
uptake. 
 
5.4.4. Effect of nanoparticles on näive T cells proliferation 
To investigate the processing pathway of the OVA and evaluate the cross-presentation 
efficiency after delivery using S-NPs and Dex-NPs, the NPs were incubated with 
BMDCs and CD8+ T cells (OT-I cells) or CD4+ T cells (OT-II cells), and the proliferation 
of naïve T cells was evaluated (Figure 5A and B). Serial dilutions of NPs were tested 
to provide OVA concentrations of 0.08-10 µg/ml. Soluble antigen and P-NPs were  






















Figure 5. Effect of NPs on the antigen presentation pathway investigated as the proliferation 
of näive T cells co-cultered with BMDCs and NPs (mean ± SD, n=3). A) Effect on proliferation 
of OT II (CD4+, helper T cells, Th) and B) OT I (CD8+, cytotoxic T cells, CTL). 
 
 
ineffective to stimulate the proliferation of neither CD8+ nor CD4+ cells. S-NPs with 2 
µg/ml OVA resulted in enhancement of CD4+ proliferation compared to soluble OVA. 
However, higher concentration of S-NPs failed to induce the proliferation of CD4+, this 
can be attributed to the possible cytotoxic effect of the positively charged nanoparticles 
on T cells, while no proliferation of CD8+ cells was observed. However, PEI-
functionalized nanoparticles were reported to induce cross presentation of antigen (6), 
PLL-functionalized nanoparticles were not efficient in antigen cross presentation as 
they failed to activate CD8+ cells. Interestingly, Dex-NPs efficiently enhanced the 
proliferation of both CD8+ and CD4+. This means that OVA was successfully 
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presented along both MHC class I and II pathways, respectively. This can be attributed 
to the potential protection of OVA in the endosome that turned into efficient cross-
presentation of OVA (30). Consequently, Dex-NPs present a promising nanovaccine 
for allergy vaccination as well as anti-viral and tumor vaccination. 
 
5.4.5. Transcutaneous delivery of nanoparticles using P.L.E.A.S.E technology 
Due to the richness of skin in APCs, it is an attractive route for vaccine administration 
(33). However, skin is a firm tissue and impermeable barrier that resists the permeation  
of molecules larger than 500 Da (34). Stratum corneum is the keratinized outermost 
layer of the skin that represents the real physical barrier (35) and also efficiently 
prevents nanoparticles’ penetration (36, 37). Laser skin microporation is a promising, 
reliable and painless technique for overcoming the stratum corneum barrier and 
delivering macromolecules and nanoparticles into viable skin. Pulsed-red laser light is 
applied to skin, where the water in the tissue absorbs the light energy and evaporates 
fast disrupting the tissue, forming pores at the site of application. P.L.E.A.S.E.® 
(Precise Laser Epidermal System) device is developed by Pantec Biosolutions for 
controlled skin microporation. The device employs a diode-pumped Erbium:yttrium-
aluminium-garnet (ER: YAG) laser at wavelength 2.94 μm which is the absorption peak 
of water molecules. The device allows for controlling the number of pores per unit area 
as well as the depth of the micropores by controlling the laser fluence (energy per unit 
area) and the number of pulses (33). The device was applied to human skin with 
fluence 56.8 J/cm2 that was efficient to create micropores as shown in Figure 6A. 
Examination of skin longitudinal sections by CLSM after nanoparticles application 
revealed the following: the formation of the microspores through the epidermis leaving 
the dermis beneath intact and the applied nanoparticles appeared to be deposited and 
lining the pores (Figure 6B). Consequently, the technology is a potential promising 
method for delivering nanoparticles loaded with antigens to dendritic cells in epidermis 





















Figure 6. Laser skin microporation of full thickness human skin using P.L.E.A.S.E.® (Precise 
Laser Epidermal System) device. Skin area of 10 mm size was treated with infra-red laser at 
fluence 56.8 J/cm2 with microporation density 10 % A) magnified images of skin surface after 
microporation and the micropores are indicated by arrows. B) CLSM image of longitudinal skin 
section showing the micropores in the epidermis layer with NPs depositions in the pores 
indicated by red fluorescence. 
 
 
5.5. Conclusion  
Theranostic gelatin nanoparticles for delivery of OVA as model antigen were 
developed. The imaging agent was a novel NIR-emitting gold and silver alloy 
nanoclusters that were synthesized in presence of gelatin and thus attached to gelatin 
backbone. Different designs of the nanoparticles were introduced to serve different 
functions and their effect on the antigen processing pathway by dendritic cells have 
been investigated. Positively charged nanoparticles displaying the antigen over the 
surface resulted in fast release of the antigen, efficient uptake by BMDCs and antigen 
presentation to MHC II that enhance the proliferation of CD4+. However, the 
cytotoxicity of the nanoparticles limited their working and efficient concentration range. 
On the other hand, encapsulation of OVA within gelatin nanoparticles and cross-linking 
resulted in slow release of the antigen. This can help to avoid pre-mature release of 
the antigen before being taken up by dendritic cells with potential protection of OVA 













mannose receptors in dendritic cells, resulted in high uptake of the particles, which was 
evaluated by flow cytometry analysis and confirmed by CLSM imaging. Successfully, 
the nanoparticles modulated the pathway of antigen presentation to be displayed by 
both MHC II and MHC I to result in enhanced proliferation of both CD4+ and CD8+, 
respectively. The developed formulation represents a promising approach for vaccine 
development against allergy as well as viruses/tumors.  
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6. Summary, Conclusion and Outlook  
 
In the current research, we have developed theranostic nanoparticles for antigen 
delivery and modulation of immune response. Delivering nanoparticles 
transcutaneously is a promising route of administration, due to the richness of skin in 
immune cells. Accordingly, through the thesis we have been working on the following: 
- Development of the imaging agent that provides the ability to be incorporated 
into gelatin drug carriers for cell and tissue imaging.  
- Development of dissolving microneedles for the nanoparticles delivery into skin 
- Design of nanoparticle formulations for antigen delivery and modulation of 
immune response 
 
Gold nanoclusters as a novel imaging agent have been synthesized using gelatin, a 
well-established pharmaceutical compound, as a reducing and templating agent. The 
reaction conditions were optimized in terms of gold and gelatin concentration and pH. 
Further, the reaction was assisted by the addition of glutathione to be a source of the 
reducing thiol groups.  This resulted in 50-nm red shift of the nanoclusters’ 
fluorescence to be 700 nm, giving the advantage of imaging in the near infra-red 
region, within the optical window of tissues. Additionally, the stability of the 
nanoclusters fluorescence against pH and enzymatic degradation have been fortified. 
For enhancement of the fluorescence intensity, silver ions have been used to modify 
the nanoclusters either by doping during or post-synthesis of the clusters. This resulted 
in 3-fold enhancement of the fluorescence quantum yield. The structure of the 
nanoclusters have been studied using X-Ray Photoelectron Spectroscopy (XPS) and 
correlated to their properties. The selected formulation of gold and silver alloy 
nanoclusters allowed to preserve the integrity of gelatin as examined by Fourier 
transform infrared spectrometry (FT-IR) and matrix-assisted laser 
desorption/ionization time of flight mass spectroscopy (MALDI-TOF MS). Further, the 
fluorescent gelatin was used to synthesize gelatin nanoparticles using two-step 
desolvation method and N-(3-Dimethylaminopropyl)-N′-ethylcarbodiimide 
hydrochloride (EDC) as a zero-length cross linker in presence of N-
Hydroxysuccinimide (NHS). The nanoparticles were introduced in skin by dissolving 







microneedles and imaged simultaneously with skin autofluorescence by confocal laser 
scanning microscopy (CLSM) using spectral analysis and linear unmixing. Introduction 
of the nanoparticles into skin was achieved using dissolving microneedles. 
 
Dissolving microneedles with new design have been developed for the delivery of the 
nanoparticles into skin. 3D-printing has been used as a cost-effective method to build 
a positive master for the preparation of microneedle patches. Microneedle designs 
inspired from the Japanese sword ‘tanto-blade’ have been produced successfully using 
a desktop DLP 3D printer. The positive molds were used to prepare a negative replica 
by polydimethylsiloxane (PDMS) casting. The latter was used for molding 
microneedles made of polyvinyl alcohol (PVA)/sucrose and loaded with the gold and 
silver alloy nanoclusters-modified gelatin nanoparticles. The force required for 
microneedles insertion in a skin surrogate was as low as 10.6 N. They were robust 
enough for insertion as the fracture force required to break or compress the 
microneedles’ tips was twice that of the insertion force. The fluorescent particles were 
imaged by CLSM in vitro to investigate the distribution of the nanoparticles in the 
microneedles’ matrix and their release in phosphate buffer saline. Further the 
microneedles patch was modified by carving a channel in each of the four corners of 
the square patch. Small volume of buffer was added post-insertion in skin, and resulted 
in fast separation of the microneedles from the base into skin. This resulted in 
decreasing the application time to 1 min. Imaging of the microneedles in human skin 
revealed that they can reach a depth of 550 µm.After being succeeded in setting up a 
system to deliver the fluorescent drug carriers across the stratum corneum, the loading 
of the carriers with relevant macromolecular drug was further investigated.  
 
The fluorescent gold and silver nanoclusters-modified gelatin nanoparticles were 
loaded with ovalbumin as a model antigen. Two different designs of the nanoparticles 
have been introduced: 
1) S-NPs: Ovalbumin was surface loaded post-synthesis of the nanoparticles. This 
was achieved by electrostatic interaction of ovalbumin to positively charged 
poly-L-lysine modified gelatin nanoparticles. The nanoparticles showed particle 
sizes with a z-avg of 210.5 nm, poly dispersity index (PDI) of 0.102 and zeta 
potential of +25.6 mV. 







2) Dex-NPs: Ovalbumin was encapsulated within the gelatin nanoparticles’ matrix 
and cross linked using EDC/NHS. The surface of the nanoparticles was 
functionalized by dextran to potentially target the mannose-receptors on 
dendritic cells. This was achieved by the electrostatic interaction between 
dextran sulphate and poly-L-lysine modified gelatin nanoparticles. The 
nanoparticles showed particle sizes with a z-avg of 300.5 nm, PDI of 0.194 and 
zeta potential of -23.9 mV. 
 
The release of ovalbumin was tested from both of the nanoparticles in PBS, where S-
NPs showed a burst release followed by slower release phase, while Dex-NPs showed 
no burst effect but slow extended release. Dex-NPs showed no cytotoxicity toward 
bone marrow-derived dendritic cells (BMDCs), while S-NPs where cytotoxic at higher 
concentration equivalent to 40 µg/ml ovalbumin. The nanoparticles uptake was 
quantitatively evaluated by flow cytometry to show superior uptake of Dex-NPs by 
BMDCs compared to S-NPs and plain gelatin nanoparticles (P-NP). CLSM imaging 
confirmed the internalization of Dex-NPs by BMDCs. Both Dex-NPs and S-NPs had 
the ability to induce the activation of BMDCs as evaluated by CD40, CD80 and CD86 
activation markers and MHC class II molecules. The effect of the nanoparticles on the 
proliferation of näive T cells co-cultured with BMDCs have been studied. Dex-NPs have 
showed the ability to enhance the proliferation of both CD4+ and CD8+. This can be 
attributed to the high uptake of the nanoparticles and/or the ability of the nanoparticles 
to induce cross-presentation of the antigen by protecting the antigen form the 
lysosomal degradation, so it can escape to the cytosol. Thus, these nanoparticles have 
great potential to be used as effective vaccine against allergy, viruses and tumors. 
 
For transcutaneous delivery of gelatin nanoparticles, microneedles were investigated 
and also preliminary studies have been done during the thesis research work using the 
P.L.E.A.S.E technology on human skin. The device induced micropores formation, 
where the applied gelatin nanoparticles deposited in, as examined by CLSM. Finally, 
Dex-NPs are promising theranostic nanovaccines that can be further applied for in vivo 
pre-clinical studies. The nanoparticles can be introduced transcuatenously by 














Figure S1. A scheme representing the microscopic chamber setup for skin examination using 
confocal microscopy, where the skin is replaced inside a ring over a PBS buffer-soaked filter 



















Figure S2. Emission spectra resulted from the interaction of different gold chloride 










Figure S3. A) TEM image of gold nanoparticles formed upon the interaction of 30 mM Au with 



















Figure S4. A) Emission spectra comparing the efficiency of gelatin A and B for the formation 
of AuNCs using 5 mM gold chloride, B) Fluorescence intensity at 640 nm resulted after 












Figure S5. Effect of multiplication of gelatin concentration on the fluorescence intensity of 
















Figure S6. Effect of GSH concentration on the fluorescence spectra of gelatin-stabilized 
AuNCs.  
Figure S7. Effect of reaction pH and time on the gelling properties of AuNCs-modified gelatin 

























Figure S8. A) TEM images of Aug and AuS (10,000x magnification) with inserts showing the 
measured size distribution (n=30). Calculated average size is 0.74 + 0.24 nm and 1.31 + 0.35 
nm for Aug and AuS, respectively and B) CLSM images upon excitation at 405 nm. The yellow 




















Figure S9. Formation of alloy AuAgNCs; A) Effect of Ag : Au ratio on the emission spectra 
while excitation at 368 nm, B) Effect of Ag : Au ratio on the fluorescence intensity at 700 nm, 
c) Effect of the lag time between the start of the reaction and doping Ag ions on the 












Figure S10. Effect of interactions with Ag ions after AuS formation; A) Effect of Ag: Au molar 
ratio on the emission spectra. B), C) and D) Effect of Ag: Au molar ratio, pH and reaction time 
on the fluorescence intensity at 700 nm, respectively. 
A B 
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Figure S11. TEM images of AuS+Ag and AuAgS. The inserts show the measured size 
distribution (n=30). Calculated average size is 0.77 + 0.21 nm and 0.69+ 0.19 nm for AuS+Ag 











Figure S12. A) Absolute quantum yield of different AuNCs measured at emission range from 
196 nm to 958 nm upon excitation with different wavelengths (400-550 nm), B) Normalized 
lifetime TCSPC measurements performed with a pulsed laser diode (λ = 470 nm) and a band 












Figure S13. Ag3d5/2 of AuS+Ag, AuAgS and Aug (upper, middle and lower curve, respectively) 
























Figure S14. A) TEM images of Aug-GNPs and AuS-GNPs with different magnifications 
showing the inner distribution of AuNCs in addition to the size distribution as determined by 
the TEM images (n=50). Average size is 132.3 + 43.6 and 99.4 + 33.5 nm for Aug-GNPs and 
AuS-GNPs, respectively, B) Size (nm), zeta potential (mV) plotted on the left Y-axis and PDI 
plotted on the right Y-axis, accompanied with the size and zeta potential distribution as 




























Figure S15. TEM images of AuAgS-GNPs, b) Size distribution as measured by DLS (upper 
panel, Z-average size of 218.8 + 1.7 nm) and by TEM (lower panel, n=50, average size = 103.2 
































Figure S16. Normalized lifetime TCSPC measurements, at λex = 470 nm using an emission 
band pass filter 685/70, of AuAgS-GNPs in comparison to AuS-GNPs and Aug-GNPs. 
 
 
Figure S17.  Confocal images of AuAgS-GNPs with skin upon excitation at 405 nm. The panels 
show the separated channels of NPs (red) and skin (green) in addition to the merged signals. 
Crude fluorescence was recorded and the signals of skin and NPs were separated using linear 













Figure S18. Gating strategy to determine uptake. After gating live CD11c+ cells, cells were 
further gated by size, and doublet were excluded on a FSC-W/FSC-H plot. Nanoparticle uptake 
was quantitated based on the increase in fluorescence intensity in the BV786 channel and an 
increase in SSC. The four plots on the left side show cells incubated with 40µg/mL soluble 
OVA and the four plots on the right side cells that were incubated with 40µg/mL dextran 

























Figure S19. Gating strategy to determine BMDC activation. After gating live CD11c+ cells, 
cells were further gated by size, and doublet were excluded on a FSC-W/FSC-H plot. The 
gates for CD40, CD86, CD80, and MHC II positive cells were determined based on 












Figure S20. Gating strategy of OT-II cells. OT-II cells were first gated based on 
size/granularity, followed by exclusion of doubles on a FSH-H/FSC-W plot. Next live CD4+ 












Figure S21. Gating strategy For OT-I cells. OT-I cells were first gated based on 
size/granularity, followed by exclusion of doubles on a FSH-H/FSC-W plot. Next live CD8+ 






















Table S1. Different selected formulations of AuNCs synthesized using gelatin B (4% w/v) and 

























pH Reaction time 
Aug - - 12 3h 
AuS 10 - 11 24h 
AuS+Ag 10 0.4 11 ( to form AuNCs),  
then 7 (while adding 
Ag+) 
24h (before  Ag+ 
addition), then 3h (with 
added Ag+) 
AuAgS 10 0.4 11 6h (with no Ag+), then 










APCs Antigen presenting cells 
AuNCs Gold nanoclusters 
BMDCs Bone marrow-derived dendritic cells 
CLSM Confocal laser scanning microscopy 
CTL Cytotoxic T lymphocytes 
DAPI 4′,6-diamidino-2-phenylindole 
Dex-NPs Dextran-functionalized gelatin nanoparticles loaded with ovalbumin 
DLP Digital Light Processing 
DMEM Dulbecco's Modified Eagle's Medium 
DPBS Dulbecco’s phosphate-buffered saline 
EDC N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride 
EE Entrapment efficiency 
FT-IR Fourier transform infrared spectrometry 
GNPs Gelatin nanoparticles 
HaCat Human keratinocytes cell line 
HBSS Hank's Balanced Salt Solution buffer 
LC Loading capacity 
MALDI-TOF 
MS 
Matrix-assisted laser desorption/ionization time of flight mass 
spectroscopy 
MHC Major histocompatibility molecules 
MNs Microneedles  
MTT 3-(4,5-Dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide 
NCs Nanoclusters  
NHS N-Hydroxysuccinimide 
NPs Nanoparticles  
OD Optical density  
OVA Ovalbumin  
PDMS polydimethylsiloxane 
P-NPs Plain gelatin nanoparticles 
PVA Poly (vinyl alcohol) 
QY Quantum yield 
S-NPs Gelatin nanoparticles lo 
TEM Transmission electron microscopy  
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